<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Commun Med (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Commun Med (Lond)</journal-id><journal-title-group><journal-title>Communications Medicine</journal-title></journal-title-group><issn pub-type="epub">2730-664X</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000740</article-id><article-id pub-id-type="pmc">PMC11862225</article-id>
<article-id pub-id-type="publisher-id">774</article-id><article-id pub-id-type="doi">10.1038/s43856-025-00774-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>LRP5 promotes adipose progenitor cell fitness and adipocyte insulin sensitivity</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5979-9019</contrib-id><name><surname>Loh</surname><given-names>Nellie Y.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vasan</surname><given-names>Senthil K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rosoff</surname><given-names>Daniel B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5729-6290</contrib-id><name><surname>Roberts</surname><given-names>Emile</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>van Dam</surname><given-names>Andrea D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>Manu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7242-0598</contrib-id><name><surname>Phillips</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wesolowska-Andersen</surname><given-names>Agata</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6004-5433</contrib-id><name><surname>Neville</surname><given-names>Matt J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7801-809X</contrib-id><name><surname>Noordam</surname><given-names>Raymond</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ray</surname><given-names>David W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7475-3932</contrib-id><name><surname>Tobias</surname><given-names>Jonathan H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6414-0529</contrib-id><name><surname>Gregson</surname><given-names>Celia L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2751-1770</contrib-id><name><surname>Karpe</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5154-0785</contrib-id><name><surname>Christodoulides</surname><given-names>Constantinos</given-names></name><address><email>costas.christodoulides@ocdem.ox.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052gg0110</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0524sp257</institution-id><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution>MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, </institution><institution>University of Bristol, </institution></institution-wrap>Bristol, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jzrsm59</institution-id><institution-id institution-id-type="GRID">grid.420085.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0481 4802</institution-id><institution>National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052gg0110</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Sir William Dunn School of Pathology, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052gg0110</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Nuffield Department of Medicine, Wellcome Centre for Human Genetics, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00aps1a34</institution-id><institution-id institution-id-type="GRID">grid.454382.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7871 7212</institution-id><institution>NIHR Oxford Biomedical Research Centre, </institution><institution>OUH Foundation Trust, </institution></institution-wrap>Oxford, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xvt9f17</institution-id><institution-id institution-id-type="GRID">grid.10419.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8945 2978</institution-id><institution>Department of Internal Medicine, Section of Gerontology and Geriatrics, </institution><institution>Leiden University Medical Center, </institution></institution-wrap>Leiden, The Netherlands </aff><aff id="Aff8"><label>8</label>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Southmead Hospital, University of Bristol, Bristol, UK </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>5</volume><elocation-id>51</elocation-id><history><date date-type="received"><day>4</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">WNT signaling plays a key role in postnatal bone formation. Individuals with gain-of-function mutations in the WNT co-receptor LRP5 exhibit increased lower-body fat mass and potentially enhanced glucose metabolism, alongside high bone mass. However, the mechanisms by which LRP5 regulates fat distribution and its effects on systemic metabolism remain unclear. This study aims to explore the role of LRP5 in adipose tissue biology and its impact on metabolism.</p></sec><sec><title>Methods</title><p id="Par2">Metabolic assessments and imaging were conducted on individuals with gain- and loss-of-function <italic>LRP5</italic> mutations, along with age- and BMI-matched controls. Mendelian randomization analyses were used to investigate the relationship between bone, fat distribution, and systemic metabolism. Functional studies and RNA sequencing were performed on abdominal and gluteal adipose cells with LRP5 knockdown.</p></sec><sec><title>Results</title><p id="Par3">Here we show that LRP5 promotes lower-body fat distribution and enhances systemic and adipocyte insulin sensitivity through cell-autonomous mechanisms, independent of its bone-related functions. LRP5 supports adipose progenitor cell function by activating WNT/&#x003b2;-catenin signaling and preserving valosin-containing protein (VCP)-mediated proteostasis. <italic>LRP5</italic> expression in adipose progenitors declines with age, but gain-of-function <italic>LRP5</italic> variants protect against age-related fat loss in the lower body.</p></sec><sec><title>Conclusions</title><p id="Par4">Our findings underscore the critical role of LRP5 in regulating lower-body fat distribution and insulin sensitivity, independent of its effects on bone. Pharmacological activation of LRP5 in adipose tissue may offer a promising strategy to prevent age-related fat redistribution and metabolic disorders.</p></sec></abstract><abstract id="Abs2" abstract-type="plain-language-summary"><title>Plain language summary</title><p id="Par5">This study investigated how a protein called LRP5 affects where fat is stored in the body and how it influences metabolism (how the body uses nutrients for energy). Some people with specific changes (mutations) in the <italic>LRP5</italic> gene tend to store more fat in their lower body, which is protective against conditions such as diabetes and heart disease, while fat in the upper body can increase health risks. To understand this, we studied individuals with different <italic>LRP5</italic> mutations and conducted various tests and cell studies. We found that LRP5 plays a key role in directing fat to the lower body and helps fat cells respond better to insulin, independent of its role in bone health. These findings suggest that targeting LRP5 could help prevent unhealthy fat storage with aging and improve metabolic health.</p></abstract><abstract id="Abs3" abstract-type="web-summary"><p id="Par6">Loh et al. investigate the role of LRP5 mutations in adipose tissue biology. They demonstrate that LRP5 promotes lower-body fat distribution and enhances systemic and adipocyte insulin sensitivity, which suggests that pharmacological activation of LRP5 could prevent age-related fat redistribution and metabolic complications.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Ageing</kwd><kwd>Gene expression profiling</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation (BHF)</institution></institution-wrap></funding-source><award-id>FS/16/45/32359</award-id><principal-award-recipient><name><surname>Christodoulides</surname><given-names>Constantinos</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par7">The WNT family of secreted glycoproteins play essential roles during adult tissue homeostasis by engaging multiple intracellular signaling cascades<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In the canonical pathway, WNT binding to low-density lipoprotein (LDL)-related protein (LRP)5 and LRP6 co-receptors regulates WNT target gene expression by inhibiting glycogen synthase kinase 3 (GSK3)-dependent degradation of the transcriptional co-regulator &#x003b2;-catenin<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. GSK3 is a promiscuous kinase and WNT signaling has also been shown to protect other GSK3 target proteins from degradation, including c-MYC and cyclin-D1. This transcription-independent signaling pathway has been termed WNT-dependent stabilization of proteins (WNT/STOP)<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. WNT signaling is indispensable for normal postnatal bone accrual. Rare, homozygous, loss-of-function (LoF) <italic>LRP5</italic> mutations in humans cause profound osteoporosis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>, a phenotype recapitulated in mice with germline or osteocyte-specific <italic>Lrp5</italic> deletion<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Conversely, rare heterozygous gain-of-function (GoF) <italic>LRP5</italic> mutations lead to inherited syndromes of high bone mass (HBM)<sup><xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par8">In addition to the well-established contribution of LRP5 in skeletal homeostasis, human and animal studies have highlighted potential roles for this receptor in white adipose tissue (WAT) biology and systemic metabolism. LRP5 knockdown (KD) in 3T3-L1 preadipocytes blocked adipogenesis<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> whilst in vivo, <italic>Lrp5</italic> null mice displayed impaired glucose tolerance and high-fat diet (HFD)-induced hypercholesterolemia<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. In humans, WAT <italic>LRP5</italic> expression was diminished in insulin-resistant subjects<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and <italic>LRP5</italic>-KD in adipose progenitors (APs) led to dose- and depot-dependent effects on in vitro adipogenesis<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Furthermore, subjects with rare LoF <italic>LRP5</italic> mutations and osteoporosis had a higher prevalence of type 2 diabetes<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par9">We previously showed that alongside HBM, GoF <italic>LRP5</italic> mutations were associated with lower-body fat distribution and potentially improved systemic insulin sensitivity<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. However, a subsequent study found no causal effects of GoF <italic>LRP5</italic> mutations on glucose homeostasis<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Hence, the role of LRP5 in systemic metabolism remains controversial. Additionally, the cellular and molecular mechanisms driving the effects of LRP5 on fat distribution and potential impacts on whole-body metabolism remain unmapped. To address these questions, we conducted in vivo studies involving GoF and LoF <italic>LRP5</italic> variant carriers, Mendelian randomization (MR) analyses, functional assays using human adipocytes and APs with induced <italic>LRP5</italic>-KD, and genome-wide transcriptomic analyses in <italic>LRP5</italic>-KD APs. We demonstrate that LRP5 promotes lower-body fat distribution by supporting AP function and proteostasis and improves systemic and adipocyte insulin sensitivity. These effects are independent of LRP5&#x02019;s role in bone. Our findings suggest that activating LRP5 in WAT could be a promising strategy to prevent age-related lower-body fat loss and associated metabolic disorders.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study participants</title><p id="Par10">Study participants were recruited from the Oxford Biobank (OBB)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and from the UK-wide HBM cohort<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Fasting blood sampling, anthropometric and DXA measurements were undertaken. A sub-group also underwent oral glucose tolerance tests (OGTTs). WAT biopsies were obtained by needle biopsy from the periumbilical and buttock areas and cell fractionations were performed by collagenase treatment and centrifugation<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. All studies were approved by the Oxfordshire Clinical Research Ethics Committee. All volunteers gave written informed consent.</p></sec><sec id="Sec4"><title>Cell lines</title><p id="Par11">Immortalized APs were generated in-house by transgenesis of primary APs from a male donor with human telomerase reverse transcriptase and HPV-E7 oncoprotein. The donor, an OBB participant, provided written informed consent. Ethical approval for the fat biopsies in OBB participants was obtained from the Oxfordshire Clinical Research Ethics Committee. De-differentiated fat (DFAT) cells were derived by selection and de-differentiation of lipid-laden, in vitro differentiated immortalized human APs<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Immortalized APs stably expressing scrambled (shCON) and LRP5 (shLRP5) shRNAs were previously published<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p></sec><sec id="Sec5"><title>Doxycycline-inducible cell lines</title><p id="Par12">Oligonucleotides for shLRP5 (top: 5&#x02032;CCGGGACGCAGTACAGCGATTATATCTCGAGATATAATCGCTGTACTGCGTCTTTTT; bottom: 5&#x02032;AATTAAAAAGACGCAGTACAGCGATTATATCTCGAGATATAATCGCTGTACTGCGTC), shVCP#1 (top: 5&#x02032; CCGGGAATAGAGTTGTTCGGAATAACTCGAGTTATTCCGAACAACTCTATTCTTTTT;</p><p id="Par13">bottom: 5&#x02032;AATTAAAAAGAATAGAGTTGTTCGGAATAACTCGAGTTATTCCGAACAACTCTATTC), shVCP#4 (top: 5&#x02032; CCGGAGATCCGTCGAGATCACTTTGCTCGAGCAAAGTGATCTCGACGGATCTTTTTT;</p><p id="Par14">bottom: 5&#x02032;AATTAAAAAAGATCCGTCGAGATCACTTTGCTCGAGCAAAGTGATCTCGACGGATCT), and shCON</p><p id="Par15">(top: 5&#x02032;CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT;</p><p id="Par16">bottom: 5&#x02032;AATTAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG) were annealed and cloned into the tet-pLKO-puro doxycycline-inducible expression lentiviral vector (gift from Dmitri Wiederschain, Addgene #21915)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. DFAT cells stably expressing tet-pLKO-puro-shLRP5 (tet-shLRP5), tet-pLKO-puro-shVCP#1 (tet-shVCP#1), tet-pLKO-puro-shVCP#4 (tet-shVCP#4) and tet-pLKO-puro-shCON (tet-shCON) were generated by lentiviral transduction and selection in 2&#x02009;&#x000b5;g/ml puromycin, and maintained and plated under tetracycline-free conditions<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> (<xref rid="MOESM2" ref-type="media">Supplementary Methods</xref>).</p><p id="Par17">For shRNA-induction, plated APs were treated with doxycycline (or vehicle) for ~48&#x02013;96&#x02009;h, or differentiated 2 days post-plating in the presence of 0.05&#x02009;&#x000b5;g/ml doxycycline (or vehicle) throughout<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. For shRNA-induction in in vitro differentiated adipocytes, cells were differentiated for 13 days, then incubated in hormone-free basal media containing 0.05&#x02009;&#x000b5;g/ml doxycycline (or vehicle) for 48&#x02009;h<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Intracellular lipids were quantified using AdipoRed (Lonza) and a PHERAstar <italic>FS</italic> microplate reader (BMG Labtech).</p><p id="Par18">The SLC2A3 full-length open-reading-frame (gift from William Hahn, David Root and Jesse Boehm, Addgene #81787)<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> was cloned into the pLenti-CMVtight-Hygro-DEST (pLENTI) lentivector (gift from Guillermo de C&#x000e1;rcer, Addgene #136339). Tet-shCON and tet-shLRP5 cells co-expressing the pLENTI-SLC2A3 (or empty) vector were generated by lentiviral transduction and selection in 20&#x02009;&#x000b5;g/ml hygromycin B. shRNA and SLC2A3 expression were induced with 0.02&#x02009;&#x000b5;g/ml doxycycline.</p></sec><sec id="Sec6"><title>Supplementation and inhibition experiments</title><p id="Par19">For supplementation experiments, 5&#x02009;mM sodium pyruvate (Merck), Wnt surrogate Fc-fusion recombinant protein (Thermo Fisher Scientific, PHG0401), or vehicle were added to adipogenic media, with or without doxycycline. For GSK3 and VCP inhibition experiments, indicated concentrations of the GSK3 inhibitor CHIR99021 (Abcam) (with or without doxycycline), VCP inhibitors DBeQ (APExBio, cat#A8629) or NMS-873 (Cambridge Bioscience, cat#CAY17674), or vehicle (DMSO) were added to the growth or adipogenic media. To assess CHIR99021 effects in G2/M-arrested cells, ~50&#x02009;K cells seeded in 6-well plates were treated the next day with 0.1&#x02009;&#x000b5;g/ml doxycycline (or vehicle) for ~24&#x02009;h, then a further 24&#x02009;h with media containing 100&#x02009;ng/ml Nocodazole (or DMSO) with or without 0.1&#x02009;&#x000b5;g/ml doxycycline, followed by a 1&#x02009;h-treatment with 0.5&#x02009;&#x000b5;M CHIR99021 (or vehicle).</p></sec><sec id="Sec7"><title>Proliferation assays</title><p id="Par20">AP proliferation was assessed in 96-well plates using the CyQUANT<sup>&#x000ae;</sup> Direct Proliferation Assay (Thermo Fisher Scientific) and a PHERAstar <italic>FS</italic> microplate reader<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Doubling time was calculated using the formula: <italic>T</italic><sub><italic>d</italic></sub>&#x02009;=&#x02009;(<italic>t</italic><sub>2</sub>&#x02009;&#x02212;&#x02009;<italic>t</italic><sub>1</sub>)&#x02009;&#x000d7;&#x02009;[log (2)&#x02009;&#x000f7;&#x02009;log (<italic>q</italic><sub>2</sub>&#x02009;&#x000f7;&#x02009;<italic>q</italic><sub>1</sub>)], where&#x02009;<italic>t</italic>&#x02009;=&#x02009;time (days), <italic>q</italic>&#x02009;=&#x02009;fluorescence intensity (surrogate for cell number).</p></sec><sec id="Sec8"><title>Clonogenic potential</title><p id="Par21">Single cells were flow-sorted into 96-well plates (1 cell/well) and cultured for 15 days in conditioned media containing doxycycline or vehicle. Cell density was assessed using the CyQUANT<sup>&#x000ae;</sup> Direct assay and cell number was estimated from a standard curve.</p></sec><sec id="Sec9"><title>Apoptosis assays</title><p id="Par22">Cells were cultured for 3 days in growth media containing doxycycline or vehicle, then a further 24&#x02009;h in serum-free media containing doxycycline or vehicle. Apoptosis was assayed using Caspase-Glo 3/7 assay (Promega) and a Veritas Microplate Luminometer (Turner Biosystems). Results were normalized to cell number.</p></sec><sec id="Sec10"><title>Glucose uptake assays</title><p id="Par23">In vitro differentiated cells were incubated in either fresh hormone-free basal medium (to measure basal uptake) or basal medium containing 25&#x02009;nM insulin for 30&#x02009;min at 37&#x02009;&#x000b0;C, 5%CO<sub>2</sub>. Cells were then washed twice in HEPES-buffered saline (HBS; 140&#x02009;mM NaCl, 20&#x02009;mM HEPES, 5&#x02009;mM KCl, 2.5&#x02009;mM MgSO<sub>4</sub>, 1&#x02009;mM CaCl, pH7.4), incubated for 10&#x02009;min at room temperature in uptake buffer (10&#x02009;&#x000b5;M 2-deoxy-<sc>d</sc>-glucose and 0.024MBq/ml 2-[<sup>3</sup>H]-deoxy-<sc>d</sc>-glucose in HBS), washed twice in ice-cold 0.9% NaCl, and lysed in 1.2&#x02009;ml 50&#x02009;mM NaOH. Radioactivity was measured using 1&#x02009;ml lysate mixed with 4&#x02009;ml liquid scintillant (Perkin Elmer) in a Beckman LS6500 Multipurpose Scintillation Counter (Beckman). Results were corrected for nonspecific diffusion (cells incubated in uptake buffer containing 10&#x02009;&#x000b5;M Cytochalasin B), and normalized to protein concentration<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. For APs, only basal glucose uptake was measured.</p></sec><sec id="Sec11"><title>TOPflash reporter assay</title><p id="Par24">Tet-shCON and tet-shLRP5 cells co-expressing the 7TFC TOPflash reporter vector (gift from Roel Nusse, Addgene #24307)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> were treated with doxycycline or vehicle for 96&#x02009;h. TOPflash reporter activity was measured using the Luciferase Assay System (Promega) on a Veritas Luminometer, and normalized to mCherry fluorescence. To assess the effects of VCP inhibitor treatment on WNT/&#x003b2;-catenin signaling, APs transduced with 7TFP<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> were seeded in 24-well plates and treated with indicated concentrations of DBeQ, NMS-873, or vehicle in serum-free media for 24&#x02009;h prior to measuring TOPflash reporter activity. Results were normalized to protein concentration.</p></sec><sec id="Sec12"><title>RNA sequencing</title><p id="Par25">RNA sequencing of vehicle and doxycycline-treated tet-shCON and tet-shLRP5 APs (three independent experiments) was performed at the Oxford Genomics Centre (WTCHG, Oxford, UK) (<xref rid="MOESM2" ref-type="media">Supplementary Information</xref>). Differentially expressed genes (DEGs) were identified using the DESeq2 v1.34.0 R package<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Gene-set enrichment analysis (GSEA) was performed on DEGs with padj&#x02009;&#x0003c;&#x02009;0.05 in Metascape<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Transcription factor binding-site motif analyses of DEGs were performed using iRegulon in Cytoscape<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p></sec><sec id="Sec13"><title>Quantitative real-time PCR and western blotting</title><p id="Par26">Taqman assays and antibodies used are listed in Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">1</xref>.</p></sec><sec id="Sec14"><title>Mendelian randomization</title><p id="Par27">We performed two-sample MR to investigate the relationship between heel-estimated bone mineral density (eBMD) and anthropometric and metabolic traits. Exposure instruments were extracted from heel eBMD GWAS summary statistics from the UK Biobank (UKB)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> using extract_instruments() in TwoSampleMR (<italic>p</italic>&#x02009;&#x0003c;&#x02009;5e&#x02009;&#x02212;&#x02009;8, LD&#x02009;<italic>r</italic><sup>2</sup>&#x02009;&#x0003c;&#x02009;0.001, genetic distance&#x02009;=&#x02009;10&#x02009;Mb, 1000 Genomes Phase 3 European population reference panel). A minor allele frequency (MAF) threshold of 0.01 was used for instrumental variable (IV) selection. As outcome data we used the largest publicly available GWAS summary statistics for anthropometric traits (body mass index (BMI) and BMI-adjusted waist-to-hip ratio (WHRadjBMI)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, BMI-adjusted waist and hip circumference (WCadjBMI, HIPadjBMI)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>), MRI-derived visceral, abdominal subcutaneous, and gluteofemoral WAT volumes, adjusted for BMI and height (vatadjbmi3, asatadjbmi3, gfatadjbmi3)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, and glycemic (BMI-adjusted fasting glucose and insulin<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>) and lipid<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> traits (Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). We performed inverse variance weighted (IVW)<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> MR, with MR-Egger<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> and weighted-median<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> as sensitivity analyses, using the TwoSampleMR package (v0.5.7) in R (v4.3.1)<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Results with a <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 in the primary IVW MR analysis and in at least one of the two sensitivity analyses were considered evidence for causal association. As additional sensitivity analysis, we repeated the MRs using IVs with MAF&#x02009;&#x02265;&#x02009;0.05.</p></sec><sec id="Sec15"><title>Statistical analyses</title><p id="Par28">Statistical analyses for the human studies were carried out using SPSS. Statistical analyses for in vitro studies and graph generation were done in GraphPad, while MR and RNA-seq analyses were carried out in R. Statistical tests used are stated within figure legends and table footnotes, and detailed in <xref rid="MOESM2" ref-type="media">Supplementary Information</xref>.</p></sec><sec id="Sec16"><title>Reporting summary</title><p id="Par29">Further information on research design is available in the&#x000a0;<xref rid="MOESM7" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec17" sec-type="results"><title>Results</title><sec id="Sec18"><title>LRP5 and systemic metabolism</title><p id="Par30">To gain further insights into the role of LRP5 in systemic metabolism, we re-evaluated the glucose and lipid profiles of six individuals with HBM due to rare heterozygous GoF <italic>LRP5</italic> mutations (LRP5<sub>A242T</sub> and LRP5<sub>N198S</sub>) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Tables&#x000a0;<xref rid="MOESM2" ref-type="media">3</xref>, <xref rid="MOESM2" ref-type="media">4</xref>). Each subject was age- and BMI-matched to ten healthy volunteers. Compared to controls, GoF <italic>LRP5</italic> mutation carriers exhibited lower fasting glucose, fasting insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), HOMA of &#x003b2;-cell function (HOMA-B), and adipose tissue insulin resistance (Adipo-IR). We also examined the metabolic profile of 23 homozygous carriers of rs4988321, a low-frequency, missense <italic>LRP5</italic> variant (LRP5<sub>V667M</sub>) presumed to be LoF since it was shown to be associated with lower heel eBMD in a large GWAS<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and to account for 100% of the posterior probability of the association at this signal<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Each subject was again matched to ten healthy controls. Compared to controls, LoF <italic>LRP5</italic> cases displayed nominally higher fasting insulin, HOMA-IR, Adipo-IR, and triglycerides (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">5</xref> and Supplementary Data&#x000a0;<xref rid="MOESM4" ref-type="media">1</xref>). Finally, we conducted OGTTs in the GoF <italic>LRP5</italic> cases and ten independent controls (Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">6</xref>). In this smaller cohort, glucose and insulin levels during the OGTT were similar between cases and controls, but GoF <italic>LRP5</italic> mutation carriers exhibited reduced post-OGTT non-esterified fatty acid (NEFA) levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">6</xref>). In conclusion, LRP5 positively regulates glucose and lipid metabolism. Additionally, the increased insulin sensitivity associated with GoF <italic>LRP5</italic> mutations might be partly driven via enhanced insulin action in WAT.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of plasma biochemistry and body composition (DXA) of individuals with <italic>LRP5</italic> gain-of-function (GoF) (A242T, N198S) and <italic>LRP5</italic> loss-of-function (LoF) (V667M) variants and age, sex and BMI-matched controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2"><italic>LRP5</italic> GoF</th><th colspan="2"><italic>LRP5</italic> LoF</th></tr><tr><th/><th>Mean difference (95% CI)</th><th><italic>P</italic> value</th><th>Mean difference (95% CI)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Sex, case (controls)</td><td>4F, 2M (40F, 20M)</td><td/><td>15F, 8M (150F, 79M)</td><td/></tr><tr><td>Age (years)<sup>a</sup></td><td>2.5&#x02009;&#x000b1;&#x02009;8.3</td><td/><td>0.7&#x02009;&#x000b1;&#x02009;2.8</td><td/></tr><tr><td>BMI (kg/m<sup>2</sup>)<sup>a</sup></td><td>&#x02212;0.08&#x02009;&#x000b1;&#x02009;0.20</td><td/><td>&#x02212;0.01&#x02009;&#x000b1;&#x02009;0.04</td><td/></tr><tr><td>Z-height</td><td>0.89 (0.09, 1.69)</td><td>0.029</td><td>&#x02212;0.45 (&#x02212;0.86, &#x02212;0.04)</td><td>0.030</td></tr><tr><td>Z-weight</td><td>0.88 (0.08, 1.68)</td><td>0.032</td><td>&#x02212;0.45 (&#x02212;0.86, &#x02212;0.04)</td><td>0.030</td></tr><tr><td colspan="5">DXA measurements<sup>b</sup></td></tr><tr><td>&#x02003;Z-Fat android</td><td>&#x02212;0.49 (&#x02212;1.31, 0.32)</td><td>0.23</td><td>0.05 (&#x02212;0.48, 0.59)</td><td>0.84</td></tr><tr><td>&#x02003;Z-Fat gynoid</td><td>0.23 (&#x02212;0.60, 1.06)</td><td>0.23</td><td>&#x02212;0.51 (&#x02212;1.03, 0.02)</td><td>0.057</td></tr><tr><td>&#x02003;Z-Fat visceral</td><td>&#x02212;0.30 (&#x02212;1.13, 0.52)</td><td>0.47</td><td>0.09 (&#x02212;0.44, 0.62)</td><td>0.73</td></tr><tr><td>&#x02003;Z-Fat legs</td><td>0.89 (0.09, 1.69)</td><td>0.029</td><td>&#x02212;0.59 (&#x02212;1.11, &#x02212;0.06)</td><td>0.028</td></tr><tr><td>&#x02003;Z-Total fat mass</td><td>0.45 (&#x02212;0.37, 1.27)</td><td>0.28</td><td>&#x02212;0.10 (&#x02212;0.63, 0.43)</td><td>0.71</td></tr><tr><td>&#x02003;Z-Total fat percentage</td><td>&#x02212;0.23 (&#x02212;1.06, 0.59)</td><td>0.57</td><td>&#x02212;0.16 (&#x02212;0.69, 0.37)</td><td>0.55</td></tr><tr><td>&#x02003;Z-Android/leg fat ratio</td><td>&#x02212;1.05 (&#x02212;1.40, &#x02212;0.70)</td><td>3.29&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6&#x02009;c</sup></td><td>0.42 (&#x02212;0.10, 0.95)</td><td>0.11</td></tr><tr><td>&#x02003;Z-Total lean mass</td><td>0.34 (&#x02212;0.48, 1.16)</td><td>0.41</td><td>&#x02212;0.00 (&#x02212;0.53, 0.53)</td><td>0.99</td></tr><tr><td>&#x02003;Z-Lean mass legs</td><td>0.12 (&#x02212;0.71, 0.95)</td><td>0.77</td><td>0.02 (&#x02212;0.51, 0.56)</td><td>0.93</td></tr><tr><td>&#x02003;Z-Total BMD</td><td>3.11 (2.99, 3.24)</td><td>2.18&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;25&#x02009;c</sup></td><td>&#x02212;0.73 (&#x02212;1.24, &#x02212;0.21)</td><td>0.006</td></tr><tr><td colspan="5">Biochemistry</td></tr><tr><td>&#x02003;Z-glucose (fasting)</td><td>&#x02212;0.96 (&#x02212;1.75, &#x02212;0.16)</td><td>0.019</td><td>&#x02212;0.11 (&#x02212;0.53, 0.30)</td><td>0.58</td></tr><tr><td>&#x02003;Z-insulin (fasting)</td><td>&#x02212;0.92 (&#x02212;1.71, &#x02212;0.12)</td><td>0.025</td><td>0.40 (&#x02212;0.01, 0.81)</td><td>0.06</td></tr><tr><td>&#x02003;Z-HOMA-IR</td><td>&#x02212;0.92 (&#x02212;1.72, &#x02212;0.13)</td><td>0.024</td><td>0.39 (&#x02212;0.02, 0.79)</td><td>0.06</td></tr><tr><td>&#x02003;Z-HOMA-B</td><td>&#x02212;0.63 (&#x02212;1.05, &#x02212;0.21)</td><td>0.006<sup>c</sup></td><td>0.34 (&#x02212;0.07, 0.75)</td><td>0.11</td></tr><tr><td>&#x02003;Z-NEFA</td><td>&#x02212;0.24 (&#x02212;1.07, 0.59)</td><td>0.57</td><td>0.24 (&#x02212;0.17, 0.65)</td><td>0.25</td></tr><tr><td>&#x02003;Z-Adipo-IR</td><td>&#x02212;0.81 (&#x02212;1.25, &#x02212;0.38)</td><td>0.001<sup>c</sup></td><td>0.36 (&#x02212;0.05, 0.77)</td><td>0.09</td></tr><tr><td>&#x02003;Z-triglycerides</td><td>&#x02212;0.58 (&#x02212;1.39, 0.24)</td><td>0.16</td><td>0.38 (&#x02212;0.03, 0.79)</td><td>0.07</td></tr></tbody></table><table-wrap-foot><p>Absolute values are shown in Supplementary Tables <xref rid="MOESM2" ref-type="media">3</xref> and <xref rid="MOESM2" ref-type="media">5</xref>. Data represent mean difference (case-control) in outcome (Z-transformed) for each case within the cluster of ten age, sex and BMI-matched controls.</p><p><italic>Adipo-IR</italic> adipose tissue insulin resistance, <italic>BMD</italic> bone mineral density, <italic>BMI</italic> body mass index, <italic>CI</italic> confidence interval, <italic>DXA</italic> dual-energy X-ray absorptiometry, <italic>HOMA-IR</italic> Homeostatic Model Assessment for Insulin Resistance, <italic>HOMA-B</italic> Homeostatic Model Assessment for Insulin Secretion, <italic>NEFA</italic> non-esterified fatty acids.</p><p><sup>a</sup>Represent mean and SD of the case from its controls within each cluster.</p><p><sup>b</sup>For LoF, DXA measurements were calculated for 14 cases (10F, 4M) and their matched 139 controls on whom data were available.</p><p><sup>c</sup><italic>P</italic> value obtained by two-sample <italic>t</italic>-test (<sup>c</sup>with Welch&#x02019;s correction for unequal variance).</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><title>Plasma biochemical profile of subjects with <italic>LRP5</italic> gain-of-function (GoF) mutation and matched controls who underwent oral glucose tolerance tests.</title><p>Plasma from blood samples collected at baseline (fasting) and at 30&#x02009;min intervals (up to 2&#x02009;h time point) following oral ingestion of glucose was measured for <bold>a</bold> glucose, <bold>b</bold> insulin, and <bold>c</bold> NEFA (median AUC shown). Controls (<italic>n</italic>&#x02009;=&#x02009;10), <italic>LRP5</italic> GoF (<italic>n</italic>&#x02009;=&#x02009;6). Graphs are mean&#x02009;&#x000b1;&#x02009;SD (<bold>a</bold>) and median (IQR) (<bold>b</bold>, <bold>c</bold>). Statistical significance was assessed by two-tailed unpaired Student&#x02019;s <italic>t</italic>-test (<bold>a</bold>) and Mann&#x02013;Whitney test (<bold>b</bold>, <bold>c</bold>).</p></caption><graphic xlink:href="43856_2025_774_Fig1_HTML" id="d33e1228"/></fig></p></sec><sec id="Sec19"><title>LRP5 and fat distribution</title><p id="Par31">Compared to controls, GoF <italic>LRP5</italic> variant carriers had markedly higher total BMD. Moreover, despite no differences in total fat mass, they exhibited higher leg fat mass and a lower android-to-leg fat mass ratio (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Conversely, LoF <italic>LRP5</italic> cases displayed lower total BMD and leg fat mass than controls. Consistent with these findings, subcutaneous WAT <italic>LRP5</italic> expression negatively correlated with the android-to-leg fat ratio in both abdominal and gluteal WAT in women, and in gluteal WAT in men (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">1a&#x02013;d</xref>). To gain mechanistic insights of how LRP5 influences regional adiposity, we analyzed <italic>LRP5</italic> expression in fractionated WAT from another cohort of 43 females with available DXA data (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">7</xref>). In age- and percent fat mass-adjusted partial correlations, both abdominal and gluteal AP <italic>LRP5</italic> expression positively correlated with lower-body fat mass. No robust correlations between mature adipocyte <italic>LRP5</italic> expression and regional adiposity were identified. Finally, <italic>LRP5</italic> mRNA abundance was higher in the stromovascular (SVF) than the adipocyte fraction of both subcutaneous abdominal and gluteal WAT, with the highest expression within the AP fraction (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">1e&#x02013;g</xref>). These findings collectively underscore that LRP5 promotes a lower-body fat distribution and point to APs as the likely effector cells.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Partial correlations (Spearman&#x02019;s) of measurements of body-fat distribution (DXA), with <italic>LRP5</italic> mRNA levels from abdominal and gluteal adipose tissue fractions from 43 women, adjusted for age, and % total fat mass</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">SC abdominal APs</th><th colspan="2">Gluteal APs</th><th colspan="2">Abdo adipocytes</th><th colspan="2">Glut adipocytes</th></tr><tr><th>Traits</th><th><italic>&#x003c1;</italic></th><th><italic>P</italic></th><th><italic>&#x003c1;</italic></th><th><italic>P</italic></th><th><italic>&#x003c1;</italic></th><th><italic>P</italic></th><th><italic>&#x003c1;</italic></th><th><italic>P</italic></th></tr></thead><tbody><tr><td>Android fat mass (g)</td><td>&#x02212;0.143</td><td>0.4</td><td>&#x02212;0.271</td><td>0.09</td><td>0.134</td><td>0.4</td><td>0.049</td><td>0.8</td></tr><tr><td>Gynoid fat mass (g)</td><td>0.390</td><td>0.01</td><td>0.285</td><td>0.08</td><td>0.108</td><td>0.5</td><td>0.196</td><td>0.2</td></tr><tr><td>Leg fat mass (g)</td><td>0.391</td><td>0.01</td><td>0.207</td><td>0.2</td><td>0.032</td><td>0.8</td><td>0.138</td><td>0.4</td></tr><tr><td>Android/gynoid fat ratio</td><td>&#x02212;0.581</td><td>0.00008</td><td>&#x02212;0.459</td><td>0.003</td><td>&#x02212;0.033</td><td>0.8</td><td>&#x02212;0.290</td><td>0.07</td></tr><tr><td>Android/leg fat ratio</td><td>&#x02212;0.511</td><td>0.001</td><td>&#x02212;0.386</td><td>0.01</td><td>&#x02212;0.032</td><td>0.8</td><td>&#x02212;0.209</td><td>0.2</td></tr></tbody></table><table-wrap-foot><p><italic>DXA</italic> dual-energy X-ray absorptiometry, <italic>SC</italic> subcutaneous, <italic>APs</italic> adipose progenitors.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec20"><title>Mendelian randomization of BMD and metabolic and anthropometric traits</title><p id="Par32">The primary phenotype associated with the described functional <italic>LRP5</italic> variants was a change in bone mass (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). As the skeleton has been reported to be a site of high glucose and NEFA uptake<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup> and to influence systemic metabolism through the secretion of hormones such as osteocalcin<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, we investigated the impact of BMD on systemic metabolism and fat distribution using two-sample MR. As IVs, we utilized all the independent single nucleotide variations (SNVs) located throughout the genome that were significantly associated with heel eBMD in a UKB GWAS<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Subsequently, we extracted the effect estimates for glycemic<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, lipid<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> and adiposity<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup> traits for each SNV from the largest publicly available GWAS. In univariate IVW MR analyses, higher heel eBMD had a negative impact on HIPadjBMI (<italic>&#x003b2;</italic>&#x02009;&#x000b1;&#x02009;SE&#x02009;=&#x02009;&#x02212;0.048&#x02009;&#x000b1;&#x02009;0.018, <italic>p</italic>&#x02009;=&#x02009;0.008) and MRI-determined GFAT volume adjusted for BMI and height (<italic>&#x003b2;</italic>&#x02009;&#x000b1;&#x02009;SE&#x02009;=&#x02009;&#x02212;0.102&#x02009;&#x000b1;&#x02009;0.020, <italic>p</italic>&#x02009;=&#x02009;6.41E&#x02009;&#x02212;&#x02009;7), and a positive impact on BMI-adjusted fasting insulin (<italic>&#x003b2;</italic>&#x02009;&#x000b1;&#x02009;SE&#x02009;=&#x02009;0.014&#x02009;&#x000b1;&#x02009;0.006, <italic>p</italic>&#x02009;=&#x02009;0.01) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">8</xref>). Sensitivity analyses, including MR analyses using heel eBMD IVs with MAF&#x02009;&#x02265;&#x02009;0.05, produced consistent results and found no evidence of unbalanced pleiotropy. However, directionally consistent effect estimates were observed only for the associations between heel eBMD and adiposity traits. Furthermore, at least one out of the two sensitivity analyses was significant for gfatadjbmi3 and fasting insulin. These data suggest that the metabolic and adipose phenotypes of <italic>LRP5</italic> variant carriers are independent of changes in bone mass/biology.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Two-sample MR IVW estimates of effects of heel eBMD (g/cm<sup>2</sup>) on anthropometric and metabolic traits in the European population (sex-combined)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Outcome</th><th><italic>N</italic> SNP</th><th><italic>&#x003b2;</italic></th><th>SE</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>asatadjbmi3</td><td>501</td><td>&#x02212;0.012</td><td>0.017</td><td>0.49</td></tr><tr><td>gfatadjbmi3</td><td>501</td><td>&#x02212;0.102</td><td>0.020</td><td>6.41&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;7</sup></td></tr><tr><td>vatadjbmi3</td><td>501</td><td>0.009</td><td>0.020</td><td>0.65</td></tr><tr><td>BMI</td><td>498</td><td>0.015</td><td>0.009</td><td>0.077</td></tr><tr><td>WHRadjBMI</td><td>498</td><td>0.007</td><td>0.011</td><td>0.54</td></tr><tr><td>Waist circumference (adjBMI)</td><td>368</td><td>&#x02212;0.019</td><td>0.015</td><td>0.20</td></tr><tr><td>Hip circumference (adjBMI)</td><td>368</td><td>&#x02212;0.048</td><td>0.018</td><td>0.0084</td></tr><tr><td>Fasting glucose (adjBMI)</td><td>497</td><td>0.004</td><td>0.005</td><td>0.45</td></tr><tr><td>Fasting insulin (adjBMI)</td><td>499</td><td>0.014</td><td>0.006</td><td>0.011</td></tr><tr><td>logTAG_noUKB</td><td>500</td><td>0.012</td><td>0.009</td><td>0.15</td></tr><tr><td>HDL_noUKB</td><td>499</td><td>&#x02212;0.019</td><td>0.010</td><td>0.050</td></tr><tr><td>LDL_noUKB</td><td>499</td><td>&#x02212;0.012</td><td>0.013</td><td>0.36</td></tr></tbody></table><table-wrap-foot><p><italic>asatadjbmi3</italic> BMI and height-adjusted abdominal subcutaneous adipose tissue, <italic>BMI</italic> body mass index, <italic>gfatadjbmi3</italic> BMI and height-adjusted gluteofemoral adipose tissue, <italic>eBMD</italic> estimated bone mineral density, <italic>HDL</italic> high-density lipoprotein, <italic>LDL</italic> low-density lipoprotein, <italic>TAG</italic> triglycerides, <italic>vatadjbmi3</italic> BMI and height-adjusted visceral adipose tissue, <italic>WHRadjBMI</italic> BMI-adjusted waist-to-hip ratio.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec21"><title>LRP5 cell autonomously regulates adipocyte insulin sensitivity</title><p id="Par33">To determine if LRP5 can directly regulate insulin action in adipocytes, we induced <italic>LRP5</italic>-KD using a Tet-On system in immortalized DFAT cells<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. LRP5 depletion in differentiated abdominal and gluteal adipocytes following 48-h doxycycline treatment was highly efficient (&#x0003e;90% at the protein level) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a&#x02013;c</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">2a</xref>, <xref rid="MOESM2" ref-type="media">3a</xref>), and did not lead to changes in lipid accumulation or alterations in adipogenic, adipocyte marker, and insulin pathway gene expression (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d, e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>), except for a notable reduction in adiponectin (<italic>ADIPOQ</italic>) mRNA abundance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">2d</xref>). In functional assays, LRP5 depletion was associated with reduced basal glucose uptake and decreased <italic>SLC2A1</italic> and/or <italic>SLC2A3</italic>, encoding the glucose transporters GLUT1 and GLUT3, in both abdominal and gluteal adipocytes. Additionally, it impaired insulin-stimulated glucose uptake and AKT phosphorylation selectively in abdominal adipocytes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f&#x02013;h</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">2k</xref>, l, <xref rid="MOESM2" ref-type="media">3b</xref>). In complementary experiments, <italic>LRP5</italic> expression exhibited a strong positive correlation with <italic>ADIPOQ</italic> expression in primary mature adipocytes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2i, j</xref>). We conclude that LRP5 directly regulates adipocyte glucose uptake, insulin sensitivity and <italic>ADIPOQ</italic> expression.<fig id="Fig2"><label>Fig. 2</label><caption><title>Effects of doxycycline (dox)-induced <italic>LRP5</italic>-knockdown on the expression of adipogenic genes and on basal and stimulated glucose uptake in in-vitro differentiated abdominal and gluteal DFAT cells.</title><p><bold>a</bold> Light microscopy of abdominal (Abdo) and gluteal (Glut) adipose progenitors (APs) after 12 days of adipogenic differentiation. Scale bar&#x02009;=&#x02009;50&#x02009;&#x000b5;m. <italic>LRP5</italic> expression was assessed in DFAT stable cell lines at day 15 of adipogenic differentiation by <bold>b</bold> qRT-PCR (<italic>n</italic>&#x02009;=&#x02009;6 experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.0002) and <bold>c</bold> western blotting, following ~48-h treatment with 0.05&#x02009;&#x000b5;g/ml doxycycline or vehicle (veh) in hormone-free basal media. <bold>d</bold> qRT-PCR analyses of adipogenic genes <italic>PPARG2</italic>, <italic>CEBPA</italic> and <italic>ADIPOQ</italic> in in-vitro differentiated cells from (<bold>b</bold>) (<italic>n</italic>&#x02009;=&#x02009;6<bold>;</bold>
<italic>ADIPOQ</italic>: (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.02; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.03). <bold>e</bold> Adipogenesis, assessed by AdipoRed staining, was not different between groups (<italic>n</italic>&#x02009;=&#x02009;6 replicates). Basal and insulin-stimulated glucose uptake in in-vitro differentiated abdominal (<bold>f</bold>) and gluteal (<bold>g</bold>) DFAT cells following ~48-h treatment with 0.05&#x02009;&#x000b5;g/ml doxycycline or vehicle in hormone-free basal media (<italic>n</italic>&#x02009;=&#x02009;3 independent experiments; (genotype/insulin&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.0046; (genotype/insulin&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.22). <bold>h</bold> Representative western blots showing LRP5 and pAKT-S473 levels in whole cell lysates from day 15 differentiated Abdo and Glut DFAT cells following ~48-h treatment with 0.05&#x02009;&#x000b5;g/ml doxycycline or vehicle in hormone-free basal media followed by treatment with 10&#x02009;nM insulin for indicated duration. Correlations between <italic>LRP5</italic> and <italic>ADIPOQ</italic> mRNA levels in isolated mature adipocytes (ADS) from subcutaneous abdominal (<bold>i</bold>) and gluteal (<bold>j</bold>) fat biopsies from 43 females and 37 males. Non-parametric (Spearman&#x02019;s) correlations, adjusted for age, sex and BMI. Statistical significance was assessed by <bold>b</bold>, <bold>d</bold>, <bold>f</bold>, <bold>g</bold> two-way repeated measures ANOVA, and <bold>e</bold> two-way ANOVA, with Sidak&#x02019;s multiple comparisons test comparing doxycycline vs. vehicle-treated groups. qRT-PCR data were normalized to <italic>18S</italic>. Results in (<bold>b</bold>), (<bold>d</bold>), and (<bold>e</bold>) are expressed as fold-change (FC) of dox-treated relative to vehicle-treated samples. <bold>b</bold>, <bold>d</bold>&#x02013;<bold>g</bold> Histograms are means&#x02009;&#x000b1;&#x02009;SD. Actin was used as a loading control for western blots.</p></caption><graphic xlink:href="43856_2025_774_Fig2_HTML" id="d33e1934"/></fig></p></sec><sec id="Sec22"><title>Transcriptome-wide profiling of LRP5 knockdown APs</title><p id="Par34">To determine the genes and biological processes regulated by LRP5 in APs, we undertook RNA sequencing in DFAT cells with induced <italic>LRP5</italic>-KD (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a, b</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">4</xref>). <italic>LRP5</italic>-KD resulted in altered expression of 871 and 955 genes in abdominal and gluteal APs, respectively, with 584 (&#x0003e;60%) of DEGs being shared. The majority of DEGs, including all the top 30, were downregulated in both abdominal and gluteal cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). Gene ontology (GO) enrichment analysis revealed that the downregulated genes in <italic>LRP5</italic>-KD APs were enriched for pathways and processes involved in the cell cycle and carbohydrate metabolism (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d, e</xref>). The latter category included <italic>SLC2A3</italic>, encoding the high-affinity glucose transporter GLUT3, as well as genes involved in multiple steps of glycolysis and de novo lipogenesis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">5a, b</xref>). <italic>LRP5</italic>-KD was also associated with reduced expression of genes involved in ossification and WNT signaling. The upregulated genes were enriched for pathways and processes related to actin cytoskeleton and extracellular matrix organization. One of the most induced genes was <italic>DKK1</italic>, encoding a potent, extracellular LRP5/6 antagonist (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">5c</xref>). Additionally, transcription factor (TF)-binding site motif analysis of the promoters of DEGs in <italic>LRP5</italic>-KD APs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d, e</xref>) indicated that the promoters of downregulated genes were enriched for binding sites of multiple TFs involved in cell cycle regulation, including several E2F family members, TFDP1, which co-operatively regulates cell cycle genes with E2Fs, and FOXM1. In contrast, the promoters of upregulated genes were enriched for motifs bound by TFs involved in the stress response (e.g., FOS, JUN, ETS), as well as motifs for SRF and multiple TEAD TF family members, which co-operatively restrain adipogenesis by transducing cytoskeletal tension-generated mechanosensitive signaling<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. Overall, these data underscore the crucial role of LRP5 in AP biology.<fig id="Fig3"><label>Fig. 3</label><caption><title>Global transcriptional profiling reveals that LRP5 regulates multiple aspects of adipose progenitor (AP) biology.</title><p><bold>a</bold>, <bold>b</bold> Abdominal (Abdo) and gluteal (Glut) DFAT APs, stably transduced with the tetracycline-inducible control (tet-shCON) or shLRP5 (tet-shLRP5) vector were cultured in the presence of vehicle (veh) or doxycycline (dox) (final concentration of 0.1&#x02009;&#x003bc;g/ml) for 48&#x02009;h to induce shRNA expression. <italic>LRP5</italic>-knockdown (KD) was confirmed by <bold>a</bold> qRT-PCR (<italic>n</italic>&#x02009;=&#x02009;4 experiments) (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.006; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.01, and <bold>b</bold> western blot. qRT-PCR data were normalized to <italic>18S</italic> and expressed as fold-change (FC) gene expression of dox-treated samples relative to vehicle-treated samples. Histograms are means&#x02009;&#x000b1;&#x02009;SD. Statistical significance was assessed by two-way repeated measures ANOVA, with Sidak&#x02019;s multiple comparisons test comparing doxycycline vs. vehicle-treated groups. <bold>c</bold> Venn diagram showing the number of significantly (padj&#x02009;&#x0003c;&#x02009;0.05) up- and downregulated genes with doxycycline-induced <italic>LRP5</italic>-KD. Pathway enrichment analyses of genes upregulated (red) and downregulated (blue) with doxycycline-induced <italic>LRP5</italic>-KD in <bold>d</bold> abdominal and <bold>e</bold> gluteal APs. Results of transcription factor binding-site motif analysis of differentially expressed genes, with normalized enrichment scores (NES), are shown to the right. <bold>f</bold> Volcano plots of genes with padj&#x02009;&#x0003c;&#x02009;0.05 and log<sub>2</sub> fold-change (log<sub>2</sub> FC)&#x02009;&#x0003e;&#x02009;0.5 in red (upregulated) or blue (downregulated). Three genes investigated in this study are labeled. Actin was used as a loading control for western blots.</p></caption><graphic xlink:href="43856_2025_774_Fig3_HTML" id="d33e2060"/></fig></p></sec><sec id="Sec23"><title>LRP5 depletion compromises AP fitness</title><p id="Par35">Consistent with the GO enrichment analyses, induced <italic>LRP5</italic>-KD impaired proliferation in both abdominal and gluteal DFAT APs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). However, LRP5 depletion only resulted in mild mitotic defects (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">6</xref>) and was not associated with abnormal chromosome segregation (our unpublished data), which have been linked to impaired WNT/STOP signaling<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. <italic>LRP5</italic>-KD also led to increased apoptosis and impaired adipogenesis in both abdominal and gluteal APs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b, c</xref>). Time-course studies revealed that LRP5 exerts its pro-adipogenic effects mainly during early adipogenesis (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">7a</xref>). Next, we investigated the impact of <italic>LRP5</italic>-KD on the clonogenic potential of APs, i.e., their ability to &#x02018;infinitely&#x02019; produce progeny, a measure stem cell status. <italic>LRP5</italic>-KD led to a dramatic reduction in the ratio of colonies formed to the number of cells seeded (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>). <italic>LRP5</italic>-KD DFAT cells also formed much smaller colonies than their control counterparts did. Finally, we explored which signaling pathway(s) mediate the effects of LRP5 on AP biology. <italic>LRP5</italic>-KD led to diminished active &#x003b2;-catenin protein levels and reduced TOPflash promoter reporter activity consistent with impaired WNT/&#x003b2;-catenin signaling. In contrast, WNT/STOP signaling, as determined by c-MYC and cyclin-D1 protein levels was unaffected (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e, f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">8</xref>). <italic>MYC</italic> and <italic>CCND1</italic> expression were similarly unchanged in <italic>LRP5</italic>-KD cells (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">7b</xref>). Consistent results were obtained in nocodazole-treated cells arrested at G2/M when WNT/STOP signaling is maximal (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">7c, d</xref>). We conclude that LRP5, acting at least partly via WNT/&#x003b2;-catenin signaling, is essential for maintaining the functional properties of APs.<fig id="Fig4"><label>Fig. 4</label><caption><title>Effects of doxycycline-induced <italic>LRP5</italic>-knockdown (KD) on abdominal (Abdo) and gluteal (Glut) adipose progenitor (AP) biology.</title><p>Effects of doxycycline (dox)-induced <italic>LRP5</italic>-KD on: <bold>a</bold> doubling time (<italic>n</italic>&#x02009;=&#x02009;6 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.02; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.009); <bold>b</bold> apoptosis (<italic>n</italic>&#x02009;=&#x02009;6, representative of two independent experiments. Results were normalized to cell number. (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001); <bold>c</bold> adipogenesis (<italic>n</italic>&#x02009;=&#x02009;3 independent experiments, (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.04; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.07); and <bold>d</bold> clonogenic potential (<italic>n</italic>&#x02009;=&#x02009;48 clones/group, representative of two independent experiments). <bold>e</bold> Western blots of active &#x003b2;-catenin, c-MYC and cyclin-D1 in vehicle (veh) and doxycycline-treated APs. <bold>f</bold> Normalized TOPflash activity in tet-shCON/7TFC and tet-shLRP5/7TFC cells treated with vehicle or 0.1&#x02009;&#x000b5;g/ml doxycycline for 96&#x02009;h (<italic>n</italic>&#x02009;=&#x02009;4 independent experiments, (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.01; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.005). <bold>a</bold>&#x02013;<bold>c</bold>, <bold>f</bold> Histograms are means&#x02009;&#x000b1;&#x02009;SD. Statistical significance was assessed by <bold>a</bold>, <bold>c</bold>, <bold>f</bold> two-way repeated measures ANOVA, with Sidak&#x02019;s multiple comparisons test, and <bold>b</bold> two-way ANOVA with Sidak&#x02019;s multiple comparisons test. Actin was used as a loading control for western blots.</p></caption><graphic xlink:href="43856_2025_774_Fig4_HTML" id="d33e2240"/></fig></p></sec><sec id="Sec24"><title>Mechanisms whereby LRP5 promotes AP fitness</title><p id="Par36"><italic>LRP5</italic>-KD was shown to profoundly suppress growth in mouse mammary epithelial cells due to reduced glucose uptake<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. WNT-LRP5 signaling was further reported to stimulate osteoblastogenesis by promoting glucose uptake and aerobic glycolysis<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Consistent with these reports and the RNA-sequencing data, we observed markedly diminished glucose uptake in <italic>LRP5</italic>-KD APs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a, b</xref>). However, supplementing the differentiation media with high-dose pyruvate (5&#x02009;mM), the three-carbon end-product of glycolysis, failed to rescue adipogenesis (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref>). We subsequently rescued the expression of <italic>SLC2A3</italic> in abdominal <italic>LRP5</italic>-KD cells, which normalized glucose uptake, but this led only in a small, albeit significant, increase in lipid accumulation during adipogenesis, and failed to reverse the impaired proliferation and increased apoptosis of these cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d&#x02013;j</xref>). Additionally, we assessed the impact of treatment with the GSK3 inhibitor CHIR99021 (0.5&#x02009;&#x000b5;M). Exposure to CHIR99021 normalized active &#x003b2;-catenin protein levels in <italic>LRP5</italic>-KD APs but had no effects on c-MYC or cyclin-D1 protein stability (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5k</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">9a</xref>&#x02013;f, <xref rid="MOESM2" ref-type="media">10</xref>). At the dose used, CHIR99021 also partially restored proliferation in abdominal <italic>LRP5</italic>-KD APs with a similar trend detected in gluteal cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5l</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">9g</xref>). Furthermore, CHIR99021 treatment throughout differentiation partially restored lipid accumulation in both abdominal and gluteal APs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5m</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">9h</xref>). The effects of CHIR99021 on TOPflash promoter reporter activity and proliferation, but not adipogenesis, where recapitulated by treatment with a WNT surrogate protein (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">11</xref>) (see <xref rid="MOESM2" ref-type="media">Supplementary Methods</xref>)<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. In summary, LRP5 promotes AP fitness, at least partly via activation of WNT/&#x003b2;-catenin signaling.<fig id="Fig5"><label>Fig. 5</label><caption><title>Restoration of <italic>SLC2A3</italic>-expression and treatment with a GSK3 inhibitor, CHIR99021, are not able to prevent defects in DFAT cells due to <italic>LRP5</italic>-knockdown (KD).</title><p><bold>a</bold>, <bold>b</bold> Abdominal (Abdo) and gluteal (Glut) DFAT adipose progenitors (APs) with doxycycline (dox)-induced <italic>LRP5</italic>-KD have reduced basal glucose uptake (<italic>n</italic>&#x02009;=&#x02009;4 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.03; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.17). <bold>c</bold> Sodium pyruvate (5&#x02009;mM) supplementation is not able to rescue adipogenesis in <italic>LRP5</italic>-KD cells (<italic>n</italic>&#x02009;=&#x02009;3 independent experiments; (genotype/dox&#x02009;&#x000d7;&#x02009;pyruvate)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.49; (genotype/dox&#x02009;&#x000d7;&#x02009;pyruvate)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.005). <bold>d</bold>&#x02013;<bold>j</bold>
<italic>SLC2A3</italic> (GLUT3)-overexpression in abdominal <italic>LRP5</italic>-KD APs increases basal glucose uptake and partially rescues adipogenesis. Dox-induced overexpression of <italic>SLC2A3</italic> in control and <italic>LRP5</italic>-KD abdominal DFAT cell lines. mRNA levels of <bold>d</bold>
<italic>LRP5</italic>, <bold>e</bold> native <italic>SLC2A3</italic>, and <bold>f</bold> total <italic>SLC2A3</italic> [(SLC2A3&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo tet-shCON</sub>
<italic>p</italic>&#x02009;=&#x02009;0.02, (SLC2A3&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo tet-shLRP5</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001] were assessed by Taqman PCR (<italic>n</italic>&#x02009;=&#x02009;6 experiments). qPCR data were normalized to <italic>18S</italic>. Effects of <italic>SLC2A3</italic>-overexpression in abdominal DFAT APs on: <bold>g</bold> basal glucose uptake (<italic>n</italic>&#x02009;=&#x02009;4 independent experiments, (genotype/dox&#x02009;&#x000d7;&#x02009;SLC2A3)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.084), <bold>h</bold> doubling time (<italic>n</italic>&#x02009;=&#x02009;6 independent experiments, (genotype/dox&#x02009;&#x000d7;&#x02009;SLC2A3)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.28), <bold>i</bold> apoptosis (<italic>n</italic>&#x02009;=&#x02009;3 independent experiments; (genotype/dox&#x02009;&#x000d7;&#x02009; SLC2A3)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.95), and <bold>j</bold> adipogenesis (<italic>n</italic>&#x02009;=&#x02009;5 independent experiments; (genotype/dox&#x02009;&#x000d7;&#x02009;SLC2A3)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.008). Impaired adipogenesis due to <italic>LRP5</italic>-KD was less severe in cells overexpressing SLC2A3 vs. empty vector (60% vs. 68% reduction, relative to vehicle-treated tet-shCON cells). <bold>k</bold>&#x02013;<bold>m</bold> Treatment with a GSK3 inhibitor, CHIR99021, partially rescues inhibition in proliferation and adipogenesis due to <italic>LRP5</italic>-KD in Abdo and Glut DFAT APs. <bold>k</bold> Representative western blots showing the effects of 0.5&#x02009;&#x000b5;M CHIR99021 (CHIR) treatment on active &#x003b2;-catenin, c-MYC and cyclin-D1. Effects of CHIR99021 treatment on: <bold>l</bold> doubling time (<italic>n</italic>&#x02009;=&#x02009;10 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.006; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.34), and <bold>m</bold> adipogenesis (<italic>n</italic>&#x02009;=&#x02009;4 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.02; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.008). Graphs are shown as a fold-change (fc) of CHIR99021-treated vs. DMSO-treated cells. In (<bold>m</bold>), cells were treated with CHIR99021 (or vehicle) throughout differentiation. See also Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">9</xref>. Statistical tests: <bold>a</bold>&#x02013;<bold>c</bold>, <bold>g</bold>&#x02013;<bold>j</bold>, <bold>l</bold>, <bold>m</bold> two-way repeated measures ANOVA, with Sidak&#x02019;s multiple comparisons test; <bold>d</bold>&#x02013;<bold>f</bold> two-way repeated measures ANOVA with Tukey&#x02019;s multiple comparisons test. Histograms are means&#x02009;&#x000b1;&#x02009;SD. Box and whisker plot: Whiskers are maximum and minimum values, and box represents median and interquartile range. Actin was used as a loading control for western blots.</p></caption><graphic xlink:href="43856_2025_774_Fig5_HTML" id="d33e2559"/></fig></p></sec><sec id="Sec25"><title>Impaired valosin-containing protein function contributes to the phenotype of LRP5 knockdown APs</title><p id="Par37">The top and second most significantly downregulated gene in abdominal and gluteal <italic>LRP5</italic>-KD APs, respectively, was <italic>VCP</italic>, encoding valosin-containing protein (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>). VCP protein levels were also lower in <italic>LRP5</italic>-KD APs and <italic>VCP</italic> mRNA abundance in primary abdominal and gluteal APs correlated positively with both <italic>LRP5</italic> gene expression (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a&#x02013;c</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">12a</xref>) and with lower-body fat distribution (Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">9</xref>). Furthermore, CHIR99021 treatment failed to prevent the downregulation in <italic>VCP</italic> expression following <italic>LRP5</italic>-KD in APs (Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">9i</xref>). Whilst VCP has multiple functions, one of its main roles is the maintenance of cellular proteostasis by facilitating the degradation of misfolded or damaged proteins through the ubiquitin proteasome system (UPS) and autophagy<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. We therefore explored if diminished VCP activity might contribute to the impaired fitness of <italic>LRP5</italic>-KD APs. Indeed, induced <italic>VCP</italic>-KD with two independent shRNAs or treatment of abdominal and gluteal DFAT cells with either a competitive (DBeQ) or an allosteric (NMS-873) chemical VCP inhibitor, led to impaired proliferation and adipogenesis independently of WNT/&#x003b2;-catenin signaling. Apoptosis was also increased in <italic>VCP</italic>-KD gluteal APs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d&#x02013;f</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">12b</xref>, <xref rid="MOESM2" ref-type="media">13</xref>, <xref rid="MOESM2" ref-type="media">14a&#x02013;c</xref>). Next, we explored the effects of VCP depletion on proteostasis. VCP is important for the maturation of autophagosomes into autolysosomes<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. Consistently, <italic>VCP</italic>-KD for 48- or 96-h led to higher levels of the autophagic substrate LC3-II in gluteal and both abdominal and gluteal APs, respectively, in keeping with defective autophagy (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">12c</xref>, <xref rid="MOESM2" ref-type="media">14d</xref>). Additionally, 96-h <italic>VCP</italic>-KD was associated with higher total ubiquitinated protein levels (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6h</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM2" ref-type="media">12d</xref>), consistent with impaired proteasomal and/or autophagic protein clearance. Finally, we examined proteostasis in <italic>LRP5</italic>-KD APs. Similar to VCP depletion, 48-h <italic>LRP5</italic>-KD was associated with LC3-II protein accumulation in gluteal cells, whilst <italic>LRP5</italic>-KD for 96-h was associated with higher levels of both LC3-II and total ubiquitinated proteins in both abdominal and gluteal APs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6i, j</xref> and Supplementary Figs.&#x000a0;<xref rid="MOESM2" ref-type="media">12e</xref>, f, <xref rid="MOESM2" ref-type="media">14e</xref>). In summary, impaired VCP function contributes to the compromised fitness of <italic>LRP5</italic>-KD APs at least partly via defective proteostasis.<fig id="Fig6"><label>Fig. 6</label><caption><title><italic>LRP5</italic>-knockdown (KD), VCP protein expression, and proteostasis.</title><p><bold>a</bold> Western blot of VCP in tet-shCON and tet-shLRP5 abdominal (Abdo) and gluteal (Glut) DFAT adipose progenitors (APs) following 4 days treatment with vehicle (veh) or 0.1&#x02009;&#x000b5;g/ml doxycycline (dox). Correlations between <italic>LRP5</italic> and <italic>VCP</italic> mRNA expression levels in human cultured primary APs from subcutaneous abdominal (<bold>b</bold>) and gluteal (<bold>c</bold>) fat biopsies from 40 to 42 females and 35 to 38 males. Non-parametric (Spearman&#x02019;s) correlations, adjusted for age, sex and BMI. qRT-PCR results are normalized to <italic>18S</italic>. <bold>d</bold>&#x02013;<bold>h</bold> Effects of doxycycline-induced <italic>VCP</italic>-KD on DFAT AP biology. <bold>d</bold> Western blots showing <italic>VCP</italic>-KD by two independent shRNAs (shVCP#1 and shVCP#4) following treatment with 0.05&#x02009;&#x000b5;g/ml doxycycline for 4 days. Effects of doxycycline-induced <italic>VCP</italic>-KD on: <bold>e</bold> doubling time (<italic>n</italic>&#x02009;=&#x02009;4 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001); <bold>f</bold> adipogenesis (vehicle or dox-treatment throughout adipogenesis, <italic>n</italic>&#x02009;=&#x02009;3 independent experiments; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Abdo</sub>
<italic>p</italic>&#x02009;=&#x02009;0.0013; (genotype&#x02009;&#x000d7;&#x02009;dox)<sub>Glut</sub>
<italic>p</italic>&#x02009;=&#x02009;0.0013). Scale bar&#x02009;=&#x02009;200&#x02009;&#x000b5;m; <bold>g</bold> autophagy (indicated by autophagic marker LC3-II); and <bold>h</bold> ubiquitinated protein (Ub) levels. Cells were treated for 4 days with 0.05&#x02009;&#x000b5;g/ml doxycycline or vehicle prior to assay in (<bold>d</bold>, <bold>e</bold>, <bold>g</bold> and <bold>h</bold>), and throughout adipogenesis in (<bold>f</bold>). Effects of 4-day doxycycline-induced <italic>LRP5</italic>-KD on autophagy (indicated by autophagic marker LC3-II) (<bold>i</bold>), and ubiquitinated protein (Ub) levels (<bold>j</bold>), in DFAT APs. Statistical analyses: <bold>e</bold>, <bold>f</bold> two-way repeated measures ANOVA with Sidak&#x02019;s multiple comparisons test. Histograms are means&#x02009;+&#x02009;SD. &#x003b1;-tubulin was used as a loading control for western blots.</p></caption><graphic xlink:href="43856_2025_774_Fig6_HTML" id="d33e2799"/></fig></p></sec><sec id="Sec26"><title>LRP5 and aging-associated fat redistribution</title><p id="Par38">Stem cell exhaustion, disabled autophagy, and loss of proteostasis are hallmarks of aging<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Consequently, we investigated if reduced LRP5 function could be linked to aging-associated WAT dysfunction. In fractionated abdominal and gluteal fat biopsies, both AP and adipocyte <italic>LRP5</italic> expression correlated negatively with donor age (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7a</xref>). <italic>LRP5</italic> expression also exhibited the strongest negative correlation with age in WAT among all tissues in GTEx (<ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org">www.gtexportal.org</ext-link>) (Supplementary Data&#x000a0;<xref rid="MOESM5" ref-type="media">2</xref>). Furthermore, stable <italic>LRP5</italic>-KD, which was more efficient in gluteal than abdominal APs (72% vs. 26%), was associated with the induction of senescence markers in gluteal APs especially post-induction of differentiation including <italic>MCP-1</italic>, <italic>IL-6</italic>, <italic>CDKN1A</italic>, and <italic>IL1A</italic> (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7b</xref>). Consistently, women carrying GoF <italic>LRP5</italic> variants displayed a lower android-to-leg fat ratio than BMI-matched women who were to 5&#x02013;20 years younger (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7c</xref> and Supplementary Tables&#x000a0;<xref rid="MOESM2" ref-type="media">10</xref>, <xref rid="MOESM2" ref-type="media">11</xref>). In stark contrast, age- and BMI-matched controls of GoF LRP5 cases exhibited a higher android-to-leg fat ratio than their younger counterparts (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7c</xref> and Supplementary Tables&#x000a0;<xref rid="MOESM2" ref-type="media">10,</xref><xref rid="MOESM2" ref-type="media"> 11</xref>). GoF <italic>LRP5</italic> cases were also protected from age-associated bone loss. We conclude that diminished LRP5 activity might contribute to the aging-associated loss of gluteofemoral fat mass consequent to AP functional decline and senescence.<fig id="Fig7"><label>Fig. 7</label><caption><title>LRP5 and aging.</title><p><bold>a</bold>
<italic>LRP5</italic> mRNA expression in human cultured primary adipose progenitors (APs) and isolated adipocytes is reduced with donor age. Correlations between <italic>LRP5</italic> mRNA levels in abdominal (Abdo) and gluteal (Glut) APs and adipocytes (ADS), and donor age. Non-parametric (Spearman&#x02019;s) correlations, adjusted for sex and BMI. <bold>b</bold> Expression of senescence markers is increased with constitutive <italic>LRP5</italic>-knockdown (KD) in undifferentiated and in vitro differentiated immortalized APs. shCON&#x02009;=&#x02009;control cells, shLRP5&#x02009;=&#x02009;<italic>LRP5</italic>-KD cells. (experimental replicates: AP cells, <italic>n</italic>&#x02009;=&#x02009;7; d14 cells: for <italic>LRP5</italic>, <italic>MCP1</italic> and <italic>IL6</italic> qRT-PCR, <italic>n</italic>&#x02009;=&#x02009;7 [<italic>n</italic>&#x02009;=&#x02009;6 for Abdo shCON], for <italic>CDKN1A</italic> and <italic>IL1A</italic> qRT-PCR: <italic>n</italic>&#x02009;=&#x02009;4 for Abdo d14 and <italic>n</italic>&#x02009;=&#x02009;5 for Glut d14). Statistics: two-way repeated measures ANOVA (for APs) and mixed-effects analysis (d14 cells), with Sidak&#x02019;s multiple comparisons test. qRT-PCR data were normalized to <italic>18S</italic>. Histograms are means&#x02009;+&#x02009;SD. <bold>c</bold> Female <italic>LRP5</italic> gain-of-function (GoF) mutation carriers are protected against age-related lower-body fat loss. Comparison of body composition (DXA) of women with <italic>LRP5</italic> GoF (A242T, N198S) variants and matched controls within a cluster of sex- and BMI-matched individuals 5&#x02013;20 years younger (see also Supplementary Tables&#x000a0;<xref rid="MOESM2" ref-type="media">10</xref> and <xref rid="MOESM2" ref-type="media">11</xref>). BMD bone mineral density.</p></caption><graphic xlink:href="43856_2025_774_Fig7_HTML" id="d33e2944"/></fig></p></sec></sec><sec id="Sec27" sec-type="discussion"><title>Discussion</title><p id="Par39">The work described extends our previous study on the role of LRP5 in systemic metabolism and fat distribution<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. By contrasting the metabolic profiles of GoF and LoF <italic>LRP5</italic> variant carriers, we show that increased LRP5 function is associated with reduced glucose and insulin levels in the fasting state, primarily reflecting hepatic insulin sensitivity. We further show that LRP5 directly promotes adipocyte insulin sensitivity both in vitro and in vivo. In line with these findings, Saarinen et al. reported a high prevalence of type 2 diabetes and impaired glucose tolerance in, mostly heterozygous, carriers of rare LoF <italic>LRP5</italic> mutations<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In contrast, another study found no impact of GoF <italic>LRP5</italic> mutations on glucose metabolism<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. It is worth noting that our GoF <italic>LRP5</italic> cases were more closely and extensively matched with controls. Additionally, our conclusions are strengthened by the contrasting metabolic phenotypes of GoF and LoF <italic>LRP5</italic> variant carriers.</p><p id="Par40">We previously showed that GoF <italic>LRP5</italic> mutations were associated with lower android-to-leg fat ratio<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Here, we confirm and expand this finding by showing that the favorable fat distribution in LRP5 GoF variant carriers is primarily driven by higher leg fat mass. Our earlier work also identified a common, intronic <italic>LRP5</italic> SNV (rs599083) linked to low spinal BMD and a nominally increased android-to-leg fat ratio<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. However, the causal gene(s) and cell type(s) responsible for the associations with the bone and potentially the adipose phenotypes at this signal remain unknown. Therefore, we revisited this finding by examining the fat distribution of carriers of LRP5<sub>V667M</sub>, a fine mapped, missense <italic>LRP5</italic> variant, predicted to be moderately pathogenic<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, which was associated with reduced heel eBMD in GWAS<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Similar to humans, homozygous LRP5<sub>V667M</sub> mutant mice displayed reduced BMD<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> and LRP5<sub>V667M</sub> was further shown to be associated with impaired WNT reporter activation<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Contrasting the phenotype of GoF <italic>LRP5</italic> cases, LRP5<sub>V667M</sub> variant carriers exhibited reduced leg fat mass.</p><p id="Par41">Animal studies have revealed that LRP5 can influence adiposity and systemic metabolism in a cell non-autonomous manner. Mice lacking <italic>Lrp5</italic> in mature osteoblasts and osteocytes displayed decreased postnatal bone mass alongside higher fat mass, elevated plasma triglycerides and NEFA on a chow diet, and glucose intolerance and insulin resistance following a HFD<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. Conversely, animals expressing a HBM <italic>Lrp5</italic> mutant allele in osteoblasts and osteocytes displayed the opposite phenotype<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. However, MR studies conducted here revealed a negative impact of higher heel eBMD on lower-body fat mass and potentially insulin sensitivity. These findings indicate that the effects of the functional LRP5 variants on these traits in humans are probably dissociated from their actions&#x000a0;in bone. Consistently, in vitro assays demonstrated that LRP5 could cell autonomously regulate adipocyte glucose uptake, insulin signaling, and <italic>ADIPOQ</italic> mRNA abundance. In this context, hypoadiponectinaemia is a marker of post-receptor adipocyte insulin resistance<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. The mechanism(s) whereby LRP5 promotes insulin action in human adipocytes remains unclear. Earlier work showed that the insulin receptor and LRP5 interact in both an insulin and WNT inducible manner in 3T3-L1 preadipocytes<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In contrast, another study demonstrated that <italic>Lrp5</italic>-deficient osteoblasts were insulin resistant due to intracellular accumulation of diacylglycerol species<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. We speculate (see below), that hyperplastic subcutaneous WAT expansion also contributes to the enhanced adipocyte insulin sensitivity associated with GoF <italic>LRP5</italic> mutations. Finally, the lack of a reduction in insulin-stimulated glucose uptake in LRP5-depleted gluteal adipocytes indicates that either LRP5 does not modulate insulin signaling in gluteal adipocytes or, alternatively, that abdominal and gluteal adipocytes have differential insulin sensitivity, possibly with the dose of insulin used (10&#x02009;nmol/L) obscuring the effect of LRP5 depletion in gluteal cells.</p><p id="Par42">Based on data showing differential LRP5 gene and protein expression specifically in the AP fraction of abdominal vs. gluteal WAT (abdominal&#x02009;&#x0003e;&#x02009;gluteal), and that stable and equivalent <italic>LRP5</italic>-KD in APs led to more pronounced defects in proliferation and adipogenesis in gluteal cells, we previously suggested that APs mediate the favorable effects of LRP5 on fat distribution<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. In line with this hypothesis, we now demonstrate that AP <italic>LRP5</italic> expression correlates selectively and positively with lower-body fat mass. Analysis of RNA-sequencing data from <italic>LRP5</italic>-KD DFAT cells also provided evidence that LRP5 stimulates both osteoblastogenesis and adipogenesis in APs, further arguing that the bone and adipose phenotypes associated with LRP5 variants are primarily driven by LRP5 actions on mesenchymal stem cell biology. The transcriptomic analyses additionally supported a role for LRP5 in stimulating AP proliferation, as well as processes which are essential for cellular energy production and biomass accumulation in proliferating cells, namely glucose uptake, glycolysis, and de novo lipogenesis. It is also noteworthy that the promoters of DEGs in <italic>LRP5</italic>-KD APs were enriched for motifs of several TFs previously shown to be induced during the mitotic clonal expansion of preadipocyte cell lines and to modulate adipogenesis, including members of the AP1 (FOS, JUN)<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, ETS<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> and E2F<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> families. This finding along with the temporal effects of <italic>LRP5</italic>-KD on adipogenesis reported here suggest that LRP5 controls in vivo adipogenesis, at least partly by promoting AP self-renewal, which precedes differentiation of one of the two resulting daughter cells<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. Consistently, it was recently reported that transient WNT signaling activation upon in vitro adipogenic induction is important in maintaining a pool of multipotent progenitors<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>.</p><p id="Par43">Functional studies supported and extended the results of the transcriptomic analyses, by demonstrating that LRP5 depletion might limit subcutaneous WAT expansion by compromising the fitness of APs; namely their renewal, proliferation, survival, and adipogenic potential. In these experiments, <italic>LRP5</italic>-KD did not result in depot-dependent effects on AP function, consistent with the near total <italic>LRP5</italic>-KD achieved in abdominal and gluteal DFAT cells using an inducible shRNA system here, as opposed to a stable system in our previous study<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Kato et al. similarly showed that the low bone mass of global <italic>Lrp5</italic>-deficient mice was secondary to osteoblast defects<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Furthermore, <italic>Lrp5</italic> deficiency led to impaired mammary stem cell maintenance<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. Collectively these studies and our own data indicate that LRP5 might promote progenitor cell fitness in diverse tissues.</p><p id="Par44">Mechanistically, <italic>LRP5</italic>-KD in APs was associated with impaired WNT/&#x003b2;-catenin but not WNT/STOP pathway activity arguing that the former is the dominant pathway in APs. Accordingly, WNT/&#x003b2;-catenin signaling activation with low-dose CHIR99021 partially rescued the impaired proliferation and, unexpectedly, the defective lipid accumulation during adipogenesis in <italic>LRP5</italic>-KD cells. In this regard, WNT/&#x003b2;-catenin signaling has been shown to potently inhibit adipogenesis<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Based on our current, as well as previous findings<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>, we speculate that this pathway has dose-dependent effects on adipogenesis, with mild activation insufficient to block and possibly stimulating early differentiation, in addition to promoting lipid accumulation via de novo lipogenesis during the latter stages of adipogenesis<sup><xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>. We further hypothesize that the differences in rescue efficacy between abdominal and gluteal <italic>LRP5</italic>-KD APs are due to differential sensitivity to CHIR99021. We observed that a WNT surrogate partially rescued proliferation in LRP5-depleted APs but, in contrast to CHIR99021, further impaired differentiation. These discrepancies could be due to functional redundancy between LRP5 and LRP6<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>, over-stimulation of WNT/&#x003b2;-catenin signaling with the WNT surrogate at the doses used, or alternatively, the independence of the effects of CHIR99021 on adipogenesis from WNT/&#x003b2;-catenin signaling. Surprisingly, supplementation with pyruvate or rescue of glucose uptake failed to improve AP fitness in <italic>LRP5</italic>-KD cells. These data argue that in high glucose culture conditions (17.5&#x02009;mM), glucose uptake and glycolysis might not be limiting for growth and differentiation of <italic>LRP5</italic>-KD cells. Alternatively, impaired glucose uptake/metabolism might be a consequence rather than a driver of this phenotype in DFAT cells.</p><p id="Par45">Our study also shows that impaired VCP activity contributes to the compromised function of <italic>LRP5</italic>-KD cells. Specifically, <italic>LRP5</italic> and <italic>VCP</italic> expression were strongly and positively correlated in primary APs and <italic>LRP5</italic>-KD in DFAT APs was associated with a striking reduction in VCP gene and protein levels. Furthermore, both genetic and chemical inhibition of VCP function replicated the phenotype of <italic>LRP5</italic>-KD cells. Finally, <italic>LRP5</italic>-KD APs displayed defective proteostasis, consistent with the key role of VCP in the UPS and autophagy. The ability to maintain a functional proteome by clearing, damaged or misfolded proteins is critical for maintaining cell fitness and survival. Accordingly, mutations in VCP cause multisystem proteinopathies, characterized by degeneration of bone and muscle, i.e., mesenchymal tissues, as well as the brain<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. We speculate that these patients also have WAT dysfunction. Our results also suggest that altered VCP function and proteostasis contribute to the adipose and metabolic phenotypes associated with functional LRP5 variants. VCP was also shown to be involved in other key cellular processes including cell cycle progression, genomic stability and endosomal sorting<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, which could also contribute to the compromised functionality of <italic>LRP5</italic>-KD cells. How LRP5 regulates VCP expression remains another important question.</p><p id="Par46">During aging, there is a progressive loss of peripheral WAT in the legs and arms coupled with the accumulation of visceral fat<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Consistently, the proliferation and differentiation capacities of APs decline during aging in both humans<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup> and mice<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. It was further shown that subcutaneous AP numbers dramatically decline with age in old mice<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. Our data demonstrate that reduced <italic>LRP5</italic> expression in APs might play a key role in the WAT redistribution and dysfunction with advancing age by leading to AP dysfunction and senescence. In line with these findings, female carriers of GoF <italic>LRP5</italic> mutations were protected from the aging-associated loss of lower-body fat. Furthermore, because LRP5 expression is lower in gluteal APs (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7b</xref> and<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>), it is likely that the gluteofemoral depot is more vulnerable to perturbations of LRP5 function through missense variants or gene expression changes. Consistently, stable <italic>LRP5</italic>-KD in APs was associated with increased expression of senescence-associated markers selectively in gluteal APs.</p><p id="Par47">In summary, we demonstrate that LRP5 promotes systemic and adipocyte insulin sensitivity. Additionally, LRP5 plays a critical role in promoting a lower-body fat distribution by maintaining the functional characteristics of APs, at least partly through WNT/&#x003b2;-catenin signaling activation and independently of this pathway by preserving proteostasis via VCP activity. <italic>LRP5</italic> expression in APs and WAT declines with age and accordingly, <italic>LRP5</italic> GoF mutation carriers were protected from the lower-body fat loss associated with aging, which we propose is the osteoporosis equivalent in WAT. Pharmacologic activation of LRP5 in WAT offers a promising approach to ameliorate the fat redistribution, metabolic complications and bone loss associated with aging.</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="43856_2025_774_MOESM1_ESM.pdf"><caption><p>Peer review file</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="43856_2025_774_MOESM2_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="43856_2025_774_MOESM3_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="43856_2025_774_MOESM4_ESM.xlsx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="43856_2025_774_MOESM5_ESM.xlsx"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="43856_2025_774_MOESM6_ESM.xlsx"><caption><p>Supplementary Data 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="43856_2025_774_MOESM7_ESM.pdf"><caption><p>Reporting summary</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s43856-025-00774-1.</p></sec><ack><title>Acknowledgements</title><p>We are grateful to the OBB and HBM volunteers, and the Clinical Research Unit nurses for their help in recruiting volunteers and with sample collection, to Dr. Toryn Poolman and Prof. Johnathan Labbadia for their advice regarding the R package and the proteostasis experiments, respectively, to Dr Enrique Toledo Maldonado for his help with scRNA-seq studies, and to Prof. Clive Osmond for advice on statistics. This work was funded by a British Heart Foundation Clinical Research Fellowship to C.C. (FS/16/45/32359). The OBB and Oxford BioResource are funded by the NIHR Oxford BRC. F.K. was funded by a BHF program grant (RG/17/1/32663). We would also like to acknowledge funding support from the NIHR Oxford BRC, Diabetes &#x00026; Metabolism Theme (IS-BRC-1215-20008), and the European Foundation for the Study of Diabetes. C.L.G. received funding for the HBM study from The Wellcome Trust (080280/Z/06/Z) and Versus Arthritis (20000). The views expressed are those of the authors. C.C. is the guarantor of this work, as such, has full access to all the study data, and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, C.C.; methodology, N.Y.L., C.C. and E.R.; investigation, N.Y.L., C.C., E.R., A.D.vD. and M.V.; formal analysis, N.Y.L., S.K.V., D.B.R., E.R., A.D.vD., D.P., A.W-A., M.J.N. and R.N.; visualization, N.Y.L., E.R., A.D.vD. and D.P.; writing&#x02014;original draft, N.Y.L. and C.C.; writing&#x02014;review and editing, N.Y.L, S.K.V., D.B.R., E.R., A.D.vD, M.V., D.P., A.W-A., M.J.N., R.N., D.W.R., J.H.T., C.L.G., F.K. and C.C.; funding acquisition, C.C. Resources, C.C., F.K., C.L.G. and J.H.T.; supervision, C.C.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par48"><italic>Communications Medicine</italic> thanks Ormond MacDougald and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.&#x000a0;<xref rid="MOESM1" ref-type="media">Peer reviewer reports</xref> are available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>Source data for Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>&#x02013;<xref rid="Fig7" ref-type="fig">7</xref> and gene counts for RNA sequencing data are available in Supplementary Data&#x000a0;<xref rid="MOESM6" ref-type="media">3</xref>. Other data and resource generated during the current study are available from the corresponding author upon reasonable request. All MR analyses were conducted using publicly available data with links to GWAS sources available in Supplementary Table&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>All analyses were completed with existing software packages.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare the following competing interests: C.C. and F.K. have received research funding from Novo Nordisk and Takeda. M.V. and A.D.vD were supported by Novo Nordisk Postdoctoral Research Fellowships. The funders had no role in the study design, analysis or reporting of the current work. M.V. is an employee of Novo Nordisk Ltd., UK (Novo Nordisk Research Centre, Oxford). N.Y.L., S.K.V., D.B.R., E.R., D.P., A.W-A., M.J.N., R.N., D.W.R., J.H.T. and C.L.G. declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>985</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Nusse, R. &#x00026; Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. <italic>Cell</italic><bold>169</bold>, 985&#x02013;999 (2017).<pub-id pub-id-type="pmid">28575679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Acebron</surname><given-names>SP</given-names></name><name><surname>Karaulanov</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>BS</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name></person-group><article-title>Mitotic wnt signaling promotes protein stabilization and regulates cell size</article-title><source>Mol. Cell</source><year>2014</year><volume>54</volume><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.04.014</pub-id><pub-id pub-id-type="pmid">24837680</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Acebron, S. P., Karaulanov, E., Berger, B. S., Huang, Y. L. &#x00026; Niehrs, C. Mitotic wnt signaling promotes protein stabilization and regulates cell size. <italic>Mol. Cell</italic><bold>54</bold>, 663&#x02013;674 (2014).<pub-id pub-id-type="pmid">24837680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development</article-title><source>Cell</source><year>2001</year><volume>107</volume><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00571-2</pub-id><pub-id pub-id-type="pmid">11719191</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. <italic>Cell</italic><bold>107</bold>, 513&#x02013;523 (2001).<pub-id pub-id-type="pmid">11719191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Maupin</surname><given-names>KA</given-names></name><name><surname>Droscha</surname><given-names>CJ</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name></person-group><article-title>A comprehensive overview of skeletal phenotypes associated with alterations in Wnt/beta-catenin signaling in humans and mice</article-title><source>Bone Res.</source><year>2013</year><volume>1</volume><fpage>27</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.4248/BR201301004</pub-id><pub-id pub-id-type="pmid">26273492</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Maupin, K. A., Droscha, C. J. &#x00026; Williams, B. O. A comprehensive overview of skeletal phenotypes associated with alterations in Wnt/beta-catenin signaling in humans and mice. <italic>Bone Res.</italic><bold>1</bold>, 27&#x02013;71 (2013).<pub-id pub-id-type="pmid">26273492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RD</given-names></name><etal/></person-group><article-title>A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait</article-title><source>Am. J. Hum. Genet.</source><year>2002</year><volume>70</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1086/338450</pub-id><pub-id pub-id-type="pmid">11741193</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Little, R. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. <italic>Am. J. Hum. Genet.</italic><bold>70</bold>, 11&#x02013;19 (2002).<pub-id pub-id-type="pmid">11741193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Boyden</surname><given-names>LM</given-names></name><etal/></person-group><article-title>High bone density due to a mutation in LDL-receptor-related protein 5</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><fpage>1513</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa013444</pub-id><pub-id pub-id-type="pmid">12015390</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. <italic>N. Engl. J. Med.</italic><bold>346</bold>, 1513&#x02013;1521 (2002).<pub-id pub-id-type="pmid">12015390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Niziolek</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>High bone mass-causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo</article-title><source>J. Bone Miner. Res.</source><year>2015</year><volume>30</volume><fpage>1822</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2514</pub-id><pub-id pub-id-type="pmid">25808845</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Niziolek, P. J. et al. High bone mass-causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo. <italic>J. Bone Miner. Res.</italic><bold>30</bold>, 1822&#x02013;1830 (2015).<pub-id pub-id-type="pmid">25808845</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Palsgaard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5)</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>12016</fpage><lpage>12026</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.337048</pub-id><pub-id pub-id-type="pmid">22337886</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Palsgaard, J. et al. Cross-talk between insulin and Wnt signaling in preadipocytes: role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5). <italic>J. Biol. Chem.</italic><bold>287</bold>, 12016&#x02013;12026 (2012).<pub-id pub-id-type="pmid">22337886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujino</surname><given-names>T</given-names></name><etal/></person-group><article-title>Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1073/pnas.0133792100</pub-id><pub-id pub-id-type="pmid">12509515</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Fujino, T. et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. <italic>Proc. Natl. Acad. Sci. USA</italic><bold>100</bold>, 229&#x02013;234 (2003).<pub-id pub-id-type="pmid">12509515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewska-Kupczewska</surname><given-names>M</given-names></name><name><surname>Stefanowicz</surname><given-names>M</given-names></name><name><surname>Matulewicz</surname><given-names>N</given-names></name><name><surname>Nikolajuk</surname><given-names>A</given-names></name><name><surname>Straczkowski</surname><given-names>M</given-names></name></person-group><article-title>Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees of insulin sensitivity</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2016</year><volume>101</volume><fpage>3079</fpage><lpage>3087</lpage><pub-id pub-id-type="doi">10.1210/jc.2016-1594</pub-id><pub-id pub-id-type="pmid">27218273</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Karczewska-Kupczewska, M., Stefanowicz, M., Matulewicz, N., Nikolajuk, A. &#x00026; Straczkowski, M. Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees of insulin sensitivity. <italic>J. Clin. Endocrinol. Metab.</italic><bold>101</bold>, 3079&#x02013;3087 (2016).<pub-id pub-id-type="pmid">27218273</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>NY</given-names></name><etal/></person-group><article-title>LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion</article-title><source>Cell Metab.</source><year>2015</year><volume>21</volume><fpage>262</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.01.009</pub-id><pub-id pub-id-type="pmid">25651180</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Loh, N. Y. et al. LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion. <italic>Cell Metab.</italic><bold>21</bold>, 262&#x02013;273 (2015).<pub-id pub-id-type="pmid">25651180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Saarinen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia</article-title><source>Clin. Endocrinol.</source><year>2010</year><volume>72</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2009.03680.x</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Saarinen, A. et al. Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. <italic>Clin. Endocrinol.</italic><bold>72</bold>, 481&#x02013;488 (2010).</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Foer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis</article-title><source>Osteoporos. Int.</source><year>2017</year><volume>28</volume><fpage>2011</fpage><lpage>2017</lpage><pub-id pub-id-type="doi">10.1007/s00198-017-3977-4</pub-id><pub-id pub-id-type="pmid">28283687</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Foer, D. et al. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. <italic>Osteoporos. Int.</italic><bold>28</bold>, 2011&#x02013;2017 (2017).<pub-id pub-id-type="pmid">28283687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Karpe</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cohort profile: the Oxford Biobank</article-title><source>Int. J. Epidemiol.</source><year>2018</year><volume>47</volume><fpage>21</fpage><lpage>21g</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx132</pub-id><pub-id pub-id-type="pmid">29040543</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Karpe, F. et al. Cohort profile: the Oxford Biobank. <italic>Int. J. Epidemiol.</italic><bold>47</bold>, 21&#x02013;21g (2018).<pub-id pub-id-type="pmid">29040543</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Gregson</surname><given-names>CL</given-names></name><etal/></person-group><article-title>&#x02018;Sink or swim&#x02019;: an evaluation of the clinical characteristics of individuals with high bone mass</article-title><source>Osteoporos. Int.</source><year>2012</year><volume>23</volume><fpage>643</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1007/s00198-011-1603-4</pub-id><pub-id pub-id-type="pmid">21455762</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gregson, C. L. et al. &#x02018;Sink or swim&#x02019;: an evaluation of the clinical characteristics of individuals with high bone mass. <italic>Osteoporos. Int.</italic><bold>23</bold>, 643&#x02013;654 (2012).<pub-id pub-id-type="pmid">21455762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>NY</given-names></name><etal/></person-group><article-title>RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2797</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16592-z</pub-id><pub-id pub-id-type="pmid">32493999</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Loh, N. Y. et al. RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro. <italic>Nat. Commun.</italic><bold>11</bold>, 2797 (2020).<pub-id pub-id-type="pmid">32493999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>M</given-names></name><etal/></person-group><article-title>TCF7L2 plays a complex role in human adipose progenitor biology, which might contribute to genetic susceptibility to type 2 diabetes</article-title><source>Metabolism</source><year>2022</year><volume>133</volume><fpage>155240</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2022.155240</pub-id><pub-id pub-id-type="pmid">35697299</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Verma, M. et al. TCF7L2 plays a complex role in human adipose progenitor biology, which might contribute to genetic susceptibility to type 2 diabetes. <italic>Metabolism</italic><bold>133</bold>, 155240 (2022).<pub-id pub-id-type="pmid">35697299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederschain</surname><given-names>D</given-names></name><etal/></person-group><article-title>Single-vector inducible lentiviral RNAi system for oncology target validation</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.4161/cc.8.3.7701</pub-id><pub-id pub-id-type="pmid">19177017</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. <italic>Cell Cycle</italic><bold>8</bold>, 498&#x02013;504 (2009).<pub-id pub-id-type="pmid">19177017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><etal/></person-group><article-title>Systematic functional interrogation of rare cancer variants identifies oncogenic alleles</article-title><source>Cancer Discov.</source><year>2016</year><volume>6</volume><fpage>714</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0160</pub-id><pub-id pub-id-type="pmid">27147599</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Kim, E. et al. Systematic functional interrogation of rare cancer variants identifies oncogenic alleles. <italic>Cancer Discov.</italic><bold>6</bold>, 714&#x02013;726 (2016).<pub-id pub-id-type="pmid">27147599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Fuerer</surname><given-names>C</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Lentiviral vectors to probe and manipulate the Wnt signaling pathway</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e9370</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009370</pub-id><pub-id pub-id-type="pmid">20186325</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Fuerer, C. &#x00026; Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. <italic>PLoS One</italic><bold>5</bold>, e9370 (2010).<pub-id pub-id-type="pmid">20186325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Love, M. I., Huber, W. &#x00026; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <italic>Genome Biol.</italic><bold>15</bold>, 550 (2014).<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1523</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. <italic>Nat. Commun.</italic><bold>10</bold>, 1523 (2019).<pub-id pub-id-type="pmid">30944313</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res.</source><year>2003</year><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. <italic>Genome Res.</italic><bold>13</bold>, 2498&#x02013;2504 (2003).<pub-id pub-id-type="pmid">14597658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>JA</given-names></name><etal/></person-group><article-title>An atlas of genetic influences on osteoporosis in humans and mice</article-title><source>Nat. Genet.</source><year>2019</year><volume>51</volume><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0302-x</pub-id><pub-id pub-id-type="pmid">30598549</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Morris, J. A. et al. An atlas of genetic influences on osteoporosis in humans and mice. <italic>Nat. Genet.</italic><bold>51</bold>, 258&#x02013;266 (2019).<pub-id pub-id-type="pmid">30598549</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Pulit</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry</article-title><source>Hum. Mol. Genet.</source><year>2019</year><volume>28</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy327</pub-id><pub-id pub-id-type="pmid">30239722</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pulit, S. L. et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. <italic>Hum. Mol. Genet.</italic><bold>28</bold>, 166&#x02013;174 (2019).<pub-id pub-id-type="pmid">30239722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Shungin</surname><given-names>D</given-names></name><etal/></person-group><article-title>New genetic loci link adipose and insulin biology to body fat distribution</article-title><source>Nature</source><year>2015</year><volume>518</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nature14132</pub-id><pub-id pub-id-type="pmid">25673412</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. <italic>Nature</italic><bold>518</bold>, 187&#x02013;196 (2015).<pub-id pub-id-type="pmid">25673412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>3771</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30931-2</pub-id><pub-id pub-id-type="pmid">35773277</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Agrawal, S. et al. Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. <italic>Nat. Commun.</italic><bold>13</bold>, 3771 (2022).<pub-id pub-id-type="pmid">35773277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>The trans-ancestral genomic architecture of glycemic traits</article-title><source>Nat. Genet.</source><year>2021</year><volume>53</volume><fpage>840</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00852-9</pub-id><pub-id pub-id-type="pmid">34059833</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. <italic>Nat. Genet.</italic><bold>53</bold>, 840&#x02013;860 (2021).<pub-id pub-id-type="pmid">34059833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The power of genetic diversity in genome-wide association studies of lipids</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04064-3</pub-id><pub-id pub-id-type="pmid">34887591</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. <italic>Nature</italic><bold>600</bold>, 675&#x02013;679 (2021).<pub-id pub-id-type="pmid">34887591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Butterworth</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Mendelian randomization analysis with multiple genetic variants using summarized data</article-title><source>Genet. Epidemiol.</source><year>2013</year><volume>37</volume><fpage>658</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1002/gepi.21758</pub-id><pub-id pub-id-type="pmid">24114802</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Burgess, S., Butterworth, A. &#x00026; Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. <italic>Genet. Epidemiol.</italic><bold>37</bold>, 658&#x02013;665 (2013).<pub-id pub-id-type="pmid">24114802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression</article-title><source>Int. J. Epidemiol.</source><year>2015</year><volume>44</volume><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmid">26050253</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bowden, J., Davey Smith, G. &#x00026; Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. <italic>Int. J. Epidemiol.</italic><bold>44</bold>, 512&#x02013;525 (2015).<pub-id pub-id-type="pmid">26050253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator</article-title><source>Genet. Epidemiol.</source><year>2016</year><volume>40</volume><fpage>304</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1002/gepi.21965</pub-id><pub-id pub-id-type="pmid">27061298</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bowden, J., Davey Smith, G., Haycock, P. C. &#x00026; Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. <italic>Genet. Epidemiol.</italic><bold>40</bold>, 304&#x02013;314 (2016).<pub-id pub-id-type="pmid">27061298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. <italic>Elife</italic><bold>7</bold>, 10.7554/eLife.34408 (2018).</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Mountjoy</surname><given-names>E</given-names></name><etal/></person-group><article-title>An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci</article-title><source>Nat. Genet.</source><year>2021</year><volume>53</volume><fpage>1527</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00945-5</pub-id><pub-id pub-id-type="pmid">34711957</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Mountjoy, E. et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. <italic>Nat. Genet.</italic><bold>53</bold>, 1527&#x02013;1533 (2021).<pub-id pub-id-type="pmid">34711957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Dirckx</surname><given-names>N</given-names></name><name><surname>Moorer</surname><given-names>MC</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name><name><surname>Riddle</surname><given-names>RC</given-names></name></person-group><article-title>The role of osteoblasts in energy homeostasis</article-title><source>Nat. Rev. Endocrinol.</source><year>2019</year><volume>15</volume><fpage>651</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/s41574-019-0246-y</pub-id><pub-id pub-id-type="pmid">31462768</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dirckx, N., Moorer, M. C., Clemens, T. L. &#x00026; Riddle, R. C. The role of osteoblasts in energy homeostasis. <italic>Nat. Rev. Endocrinol.</italic><bold>15</bold>, 651&#x02013;665 (2019).<pub-id pub-id-type="pmid">31462768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Suchacki</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3097</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16878-2</pub-id><pub-id pub-id-type="pmid">32555194</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Suchacki, K. J. et al. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. <italic>Nat. Commun.</italic><bold>11</bold>, 3097 (2020).<pub-id pub-id-type="pmid">32555194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>17119</fpage><lpage>17134</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.003608</pub-id><pub-id pub-id-type="pmid">30209132</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhang, W. et al. The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex. <italic>J. Biol. Chem.</italic><bold>293</bold>, 17119&#x02013;17134 (2018).<pub-id pub-id-type="pmid">30209132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrinelli</surname><given-names>V</given-names></name><etal/></person-group><article-title>Human adipocyte function is impacted by mechanical cues</article-title><source>J. Pathol.</source><year>2014</year><volume>233</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1002/path.4347</pub-id><pub-id pub-id-type="pmid">24623048</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Pellegrinelli, V. et al. Human adipocyte function is impacted by mechanical cues. <italic>J. Pathol.</italic><bold>233</bold>, 183&#x02013;195 (2014).<pub-id pub-id-type="pmid">24623048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Stolz</surname><given-names>A</given-names></name><name><surname>Neufeld</surname><given-names>K</given-names></name><name><surname>Ertych</surname><given-names>N</given-names></name><name><surname>Bastians</surname><given-names>H</given-names></name></person-group><article-title>Wnt-mediated protein stabilization ensures proper mitotic microtubule assembly and chromosome segregation</article-title><source>EMBO Rep.</source><year>2015</year><volume>16</volume><fpage>490</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.15252/embr.201439410</pub-id><pub-id pub-id-type="pmid">25656539</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Stolz, A., Neufeld, K., Ertych, N. &#x00026; Bastians, H. Wnt-mediated protein stabilization ensures proper mitotic microtubule assembly and chromosome segregation. <italic>EMBO Rep.</italic><bold>16</bold>, 490&#x02013;499 (2015).<pub-id pub-id-type="pmid">25656539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>EN</given-names></name><name><surname>Martin</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Fakhraldeen</surname><given-names>SA</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name></person-group><article-title>Lrp5 has a Wnt-independent role in glucose uptake and growth for mammary epithelial cells</article-title><source>Mol. Cell. Biol.</source><year>2015</year><volume>36</volume><fpage>871</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1128/MCB.00800-15</pub-id><pub-id pub-id-type="pmid">26711269</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chin, E. N., Martin, J. A., Kim, S., Fakhraldeen, S. A. &#x00026; Alexander, C. M. Lrp5 has a Wnt-independent role in glucose uptake and growth for mammary epithelial cells. <italic>Mol. Cell. Biol.</italic><bold>36</bold>, 871&#x02013;885 (2015).<pub-id pub-id-type="pmid">26711269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Esen</surname><given-names>E</given-names></name><etal/></person-group><article-title>WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation</article-title><source>Cell Metab.</source><year>2013</year><volume>17</volume><fpage>745</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.03.017</pub-id><pub-id pub-id-type="pmid">23623748</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Esen, E. et al. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. <italic>Cell Metab.</italic><bold>17</bold>, 745&#x02013;755 (2013).<pub-id pub-id-type="pmid">23623748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Receptor subtype discrimination using extensive shape complementary designed interfaces</article-title><source>Nat. Struct. Mol. Biol.</source><year>2019</year><volume>26</volume><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/s41594-019-0224-z</pub-id><pub-id pub-id-type="pmid">31086346</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Dang, L. T. et al. Receptor subtype discrimination using extensive shape complementary designed interfaces. <italic>Nat. Struct. Mol. Biol.</italic><bold>26</bold>, 407&#x02013;414 (2019).<pub-id pub-id-type="pmid">31086346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Next-generation surrogate Wnts support organoid growth and deconvolute frizzled pleiotropy in vivo</article-title><source>Cell Stem Cell</source><year>2020</year><volume>27</volume><fpage>840</fpage><lpage>851 e846</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.07.020</pub-id><pub-id pub-id-type="pmid">32818433</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Miao, Y. et al. Next-generation surrogate Wnts support organoid growth and deconvolute frizzled pleiotropy in vivo. <italic>Cell Stem Cell</italic><bold>27</bold>, 840&#x02013;851 e846 (2020).<pub-id pub-id-type="pmid">32818433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>H</given-names></name><name><surname>Weihl</surname><given-names>CC</given-names></name></person-group><article-title>The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis</article-title><source>J. Cell Sci.</source><year>2014</year><volume>127</volume><fpage>3877</fpage><lpage>3883</lpage><pub-id pub-id-type="pmid">25146396</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Meyer, H. &#x00026; Weihl, C. C. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. <italic>J. Cell Sci.</italic><bold>127</bold>, 3877&#x02013;3883 (2014).<pub-id pub-id-type="pmid">25146396</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Tresse</surname><given-names>E</given-names></name><etal/></person-group><article-title>VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD</article-title><source>Autophagy</source><year>2010</year><volume>6</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.4161/auto.6.2.11014</pub-id><pub-id pub-id-type="pmid">20104022</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Tresse, E. et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. <italic>Autophagy</italic><bold>6</bold>, 217&#x02013;227 (2010).<pub-id pub-id-type="pmid">20104022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease</article-title><source>J. Cell Biol.</source><year>2009</year><volume>187</volume><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1083/jcb.200908115</pub-id><pub-id pub-id-type="pmid">20008565</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ju, J. S. et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. <italic>J. Cell Biol.</italic><bold>187</bold>, 875&#x02013;888 (2009).<pub-id pub-id-type="pmid">20008565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Otin</surname><given-names>C</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Hallmarks of aging: an expanding universe</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>243</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.11.001</pub-id><pub-id pub-id-type="pmid">36599349</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. &#x00026; Kroemer, G. Hallmarks of aging: an expanding universe. <italic>Cell</italic><bold>186</bold>, 243&#x02013;278 (2023).<pub-id pub-id-type="pmid">36599349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>McLaren</surname><given-names>W</given-names></name><etal/></person-group><article-title>The Ensembl variant effect predictor</article-title><source>Genome Biol.</source><year>2016</year><volume>17</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">McLaren, W. et al. The Ensembl variant effect predictor. <italic>Genome Biol.</italic><bold>17</bold>, 122 (2016).<pub-id pub-id-type="pmid">27268795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Fabre</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lrp5 p.Val667Met variant compromises bone mineral density and matrix properties in osteoporosis</article-title><source>JBMR Plus</source><year>2023</year><volume>7</volume><fpage>e10741</fpage><pub-id pub-id-type="doi">10.1002/jbm4.10741</pub-id><pub-id pub-id-type="pmid">37283650</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Fabre, S. et al. Lrp5 p.Val667Met variant compromises bone mineral density and matrix properties in osteoporosis. <italic>JBMR Plus</italic><bold>7</bold>, e10741 (2023).<pub-id pub-id-type="pmid">37283650</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Collet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes</article-title><source>JBMR Plus</source><year>2018</year><volume>2</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/jbm4.10020</pub-id><pub-id pub-id-type="pmid">30283887</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Collet, C. et al. Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. <italic>JBMR Plus</italic><bold>2</bold>, 12&#x02013;21 (2018).<pub-id pub-id-type="pmid">30283887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast</article-title><source>Mol. Cell. Biol.</source><year>2015</year><volume>35</volume><fpage>1979</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1128/MCB.01343-14</pub-id><pub-id pub-id-type="pmid">25802278</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Frey, J. L. et al. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. <italic>Mol. Cell. Biol.</italic><bold>35</bold>, 1979&#x02013;1991 (2015).<pub-id pub-id-type="pmid">25802278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SP</given-names></name><name><surname>Frey</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Goh</surname><given-names>BC</given-names></name><name><surname>Riddle</surname><given-names>RC</given-names></name></person-group><article-title>Lack of Lrp5 signaling in osteoblasts sensitizes male mice to diet-induced disturbances in glucose metabolism</article-title><source>Endocrinology</source><year>2017</year><volume>158</volume><fpage>3805</fpage><lpage>3816</lpage><pub-id pub-id-type="doi">10.1210/en.2017-00657</pub-id><pub-id pub-id-type="pmid">28938444</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kim, S. P., Frey, J. L., Li, Z., Goh, B. C. &#x00026; Riddle, R. C. Lack of Lrp5 signaling in osteoblasts sensitizes male mice to diet-induced disturbances in glucose metabolism. <italic>Endocrinology</italic><bold>158</bold>, 3805&#x02013;3816 (2017).<pub-id pub-id-type="pmid">28938444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Stears</surname><given-names>A</given-names></name><name><surname>O&#x02019;Rahilly</surname><given-names>S</given-names></name><name><surname>Semple</surname><given-names>RK</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name></person-group><article-title>Metabolic insights from extreme human insulin resistance phenotypes</article-title><source>Best. Pract. Res. Clin. Endocrinol. Metab.</source><year>2012</year><volume>26</volume><fpage>145</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2011.09.003</pub-id><pub-id pub-id-type="pmid">22498245</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Stears, A., O&#x02019;Rahilly, S., Semple, R. K. &#x00026; Savage, D. B. Metabolic insights from extreme human insulin resistance phenotypes. <italic>Best. Pract. Res. Clin. Endocrinol. Metab.</italic><bold>26</bold>, 145&#x02013;157 (2012).<pub-id pub-id-type="pmid">22498245</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>YM</given-names></name><name><surname>Lane</surname><given-names>MD</given-names></name></person-group><article-title>Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>17653</fpage><lpage>17660</lpage><pub-id pub-id-type="doi">10.1074/jbc.M910445199</pub-id><pub-id pub-id-type="pmid">10749891</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Patel, Y. M. &#x00026; Lane, M. D. Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27. <italic>J. Biol. Chem.</italic><bold>275</bold>, 17653&#x02013;17660 (2000).<pub-id pub-id-type="pmid">10749891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Birsoy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis</article-title><source>Development</source><year>2011</year><volume>138</volume><fpage>4709</fpage><lpage>4719</lpage><pub-id pub-id-type="doi">10.1242/dev.067710</pub-id><pub-id pub-id-type="pmid">21989915</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Birsoy, K. et al. Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis. <italic>Development</italic><bold>138</bold>, 4709&#x02013;4719 (2011).<pub-id pub-id-type="pmid">21989915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Fajas</surname><given-names>L</given-names></name><etal/></person-group><article-title>E2Fs regulate adipocyte differentiation</article-title><source>Dev. Cell</source><year>2002</year><volume>3</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(02)00190-9</pub-id><pub-id pub-id-type="pmid">12110166</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Fajas, L. et al. E2Fs regulate adipocyte differentiation. <italic>Dev. Cell</italic><bold>3</bold>, 39&#x02013;49 (2002).<pub-id pub-id-type="pmid">12110166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting nuclear receptor NR4A1-dependent adipocyte progenitor quiescence promotes metabolic adaptation to obesity</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>4898</fpage><lpage>4911</lpage><pub-id pub-id-type="doi">10.1172/JCI98353</pub-id><pub-id pub-id-type="pmid">30277475</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Zhang, Y. et al. Targeting nuclear receptor NR4A1-dependent adipocyte progenitor quiescence promotes metabolic adaptation to obesity. <italic>J. Clin. Investig.</italic><bold>128</bold>, 4898&#x02013;4911 (2018).<pub-id pub-id-type="pmid">30277475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang Loureiro</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Wnt signaling preserves progenitor cell multipotency during adipose tissue development</article-title><source>Nat. Metab.</source><year>2023</year><volume>5</volume><fpage>1014</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1038/s42255-023-00813-y</pub-id><pub-id pub-id-type="pmid">37337125</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Yang Loureiro, Z. et al. Wnt signaling preserves progenitor cell multipotency during adipose tissue development. <italic>Nat. Metab.</italic><bold>5</bold>, 1014&#x02013;1028 (2023).<pub-id pub-id-type="pmid">37337125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Palani</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Adipogenic and SWAT cells separate from a common progenitor in human brown and white adipose depots</article-title><source>Nat. Metab.</source><year>2023</year><volume>5</volume><fpage>996</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1038/s42255-023-00820-z</pub-id><pub-id pub-id-type="pmid">37337126</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Palani, N. P. et al. Adipogenic and SWAT cells separate from a common progenitor in human brown and white adipose depots. <italic>Nat. Metab.</italic><bold>5</bold>, 996&#x02013;1013 (2023).<pub-id pub-id-type="pmid">37337126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor</article-title><source>J. Cell Biol.</source><year>2002</year><volume>157</volume><fpage>303</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1083/jcb.200201089</pub-id><pub-id pub-id-type="pmid">11956231</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. <italic>J. Cell Biol.</italic><bold>157</bold>, 303&#x02013;314 (2002).<pub-id pub-id-type="pmid">11956231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Badders</surname><given-names>NM</given-names></name><etal/></person-group><article-title>The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e6594</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0006594</pub-id><pub-id pub-id-type="pmid">19672307</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Badders, N. M. et al. The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. <italic>PLoS One</italic><bold>4</bold>, e6594 (2009).<pub-id pub-id-type="pmid">19672307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Inhibition of adipogenesis by Wnt signaling</article-title><source>Science</source><year>2000</year><volume>289</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1126/science.289.5481.950</pub-id><pub-id pub-id-type="pmid">10937998</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Ross, S. E. et al. Inhibition of adipogenesis by Wnt signaling. <italic>Science</italic><bold>289</bold>, 950&#x02013;953 (2000).<pub-id pub-id-type="pmid">10937998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Bagchi</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Wntless regulates lipogenic gene expression in adipocytes and protects against diet-induced metabolic dysfunction</article-title><source>Mol. Metab.</source><year>2020</year><volume>39</volume><fpage>100992</fpage><pub-id pub-id-type="doi">10.1016/j.molmet.2020.100992</pub-id><pub-id pub-id-type="pmid">32325263</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Bagchi, D. P. et al. Wntless regulates lipogenic gene expression in adipocytes and protects against diet-induced metabolic dysfunction. <italic>Mol. Metab.</italic><bold>39</bold>, 100992 (2020).<pub-id pub-id-type="pmid">32325263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Bagchi</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Wnt/beta-catenin signaling regulates adipose tissue lipogenesis and adipocyte-specific loss is rigorously defended by neighboring stromal-vascular cells</article-title><source>Mol. Metab.</source><year>2020</year><volume>42</volume><fpage>101078</fpage><pub-id pub-id-type="doi">10.1016/j.molmet.2020.101078</pub-id><pub-id pub-id-type="pmid">32919095</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Bagchi, D. P. et al. Wnt/beta-catenin signaling regulates adipose tissue lipogenesis and adipocyte-specific loss is rigorously defended by neighboring stromal-vascular cells. <italic>Mol. Metab.</italic><bold>42</bold>, 101078 (2020).<pub-id pub-id-type="pmid">32919095</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>16454</fpage><lpage>16466</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.362137</pub-id><pub-id pub-id-type="pmid">22433869</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Goel, S. et al. Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts. <italic>J. Biol. Chem.</italic><bold>287</bold>, 16454&#x02013;16466 (2012).<pub-id pub-id-type="pmid">22433869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Palmer, A. K. &#x00026; Jensen, M. D. Metabolic changes in aging humans: current evidence and therapeutic strategies. <italic>J. Clin. Investig.</italic><bold>132</bold>10.1172/JCI158451 (2022).</mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>AK</given-names></name><name><surname>Kirkland</surname><given-names>JL</given-names></name></person-group><article-title>Aging and adipose tissue: potential interventions for diabetes and regenerative medicine</article-title><source>Exp. Gerontol.</source><year>2016</year><volume>86</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2016.02.013</pub-id><pub-id pub-id-type="pmid">26924669</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Palmer, A. K. &#x00026; Kirkland, J. L. Aging and adipose tissue: potential interventions for diabetes and regenerative medicine. <italic>Exp. Gerontol.</italic><bold>86</bold>, 97&#x02013;105 (2016).<pub-id pub-id-type="pmid">26924669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Aging-dependent regulatory cells emerge in subcutaneous fat to inhibit adipogenesis</article-title><source>Dev. Cell</source><year>2021</year><volume>56</volume><fpage>1437</fpage><lpage>1451 e1433</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.03.026</pub-id><pub-id pub-id-type="pmid">33878347</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Nguyen, H. P. et al. Aging-dependent regulatory cells emerge in subcutaneous fat to inhibit adipogenesis. <italic>Dev. Cell</italic><bold>56</bold>, 1437&#x02013;1451 e1433 (2021).<pub-id pub-id-type="pmid">33878347</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>